Poisons Regulations 1965 (WA)
Western Australia
Poisons Act 1964
These regulations were repealed as a result of the repeal of the
Western Australia
Western Australia
Poisons Act 1964Poisons Act 1964
These regulations may be cited as the
(1) In these regulations unless the context requires otherwise —
(a) to be in charge of a hospital; or
(b) to a remote area nursing post;
(a) means supply the medicine or poison on and in accordance with a prescription duly given by a medical practitioner, a nurse practitioner, a dentist or a veterinary surgeon; and
(b) in relation to a drug of addiction, has a meaning affected by regulation 42A;
(a) a medical practitioner, pharmacist, dentist, veterinary surgeon; or
(b) a person who is the holder of a degree approved by the CEO conferred by a University of the
British Commonwealth ; or(c) a person who is eligible to be —
(i) a Fellow or Associate of the Royal Australian Chemical Institute; or
(ii) a Fellow, Associate or Licentiate of the Royal Institute of Chemistry;
or
(d) any other person approved of by the CEO;
(2) A prescription is issued electronically if it is issued under regulation 37(1A) or 51(1A).
Notes in these regulations are provided to assist understanding and do not form part of the regulations.
For the purposes of section 64B of the Act, the office of the Pharmaceutical Services Branch of the department, located at
Excluding substances included in Schedule 8 and Schedule 9 and specified drugs, the provisions of the Act do not apply to —
(a) poisons listed in Column 1 of Appendix G to the SUSMP in a product at a concentration the same or less than that specified in Column 2; and
(b) poisons in a product listed in Appendix A to the SUSMP; and
(c) paints, except when prepared for medicinal or cosmetic purposes, which contain substances included in Schedule 5; and
(d) paints, except when prepared for medicinal or cosmetic purposes, which contain poisons listed in the First, Second or Third Schedule of Appendix I to the SUSMP, if —
(i) the proportion of the poison is less than the proportion specified in those schedules; or
(ii) the proportion of the poison is within the limits specified in those schedules and the container is labelled in accordance with the provisions of Part 2 of the SUSMP.
(1) For the purpose of section 23(4B) of the Act, endorsed optometrist is prescribed as a class of endorsed health practitioner.
(2) For the purpose of section 23(4B) of the Act, in relation to the class prescribed under subregulation (1), a medicine listed in the
Endorsement for Scheduled Medicines Registration Standard for Optometrists Table 1 approved by the Australian Health Workforce Ministerial Council on 31 March 2010 is prescribed (aprescribed medicine ).(3) Under section 23(4C)(a) of the Act, the authorisation given by section 23(4B) of the Act is restricted —
(a) in relation to a prescribed medicine, to possession, use, supply, sale or prescription in relation to topical use in the eye; and
(b) in relation to phenylephrine, to phenylephrine with a maximum concentration of 5%.
An endorsed optometrist is not to be taken to be supplying within the meaning of these regulations if the endorsed optometrist uses a medicine prescribed under regulation 3A(2) in the lawful practice of his or her profession.
In this Division —
(1) For the purpose of section 23(4B) of the Act, endorsed midwife is a prescribed class of endorsed health practitioner.
(2) For the purpose of section 23(4B) of the Act, in relation to the class prescribed under subregulation (1), a medicine listed in the Prescribing Formulary is prescribed (a
prescribed medicine ).(3) Under section 23(4C)(a) of the Act, the authorisation given by section 23(4B) of the Act —
(a) in relation to a prescribed medicine, is restricted to the possession, use, supply, sale or prescription for the purposes of administration —
(i) by a route set out in the Prescribing Formulary for the medicine; and
(ii) for the duration, and subject to any restriction, for the medicine set out in the Prescribing Formulary; and
(iii) to treat a medical condition that is an indicator for the medicine set out in the Prescribing Formulary;
and
(b) in relation to a prescribed medicine that is a poison included in Schedule 8, is subject to the condition that an endorsed midwife may not prescribe the medicine for the purpose of the administration of the medicine by a person other than the endorsed midwife.
An endorsed midwife is not to be taken to be supplying within the meaning of these regulations if the endorsed midwife uses a medicine prescribed under regulation 3D(2) in the lawful practice of his or her profession.
In this Division —
(1) For the purpose of section 23(4B) of the Act, endorsed podiatrist is a prescribed class of endorsed health practitioner.
(2) For the purpose of section 23(4B) of the Act, in relation to the class prescribed under subregulation (1), a medicine listed in the Medicines List is prescribed (a
prescribed medicine ).(3) Under section 23(4C)(a) of the Act, the authorisation given by section 23(4B) of the Act —
(a) in relation to a prescribed medicine, is restricted to the possession, use, supply, sale or prescription —
(i) for the purposes of administration by a route set out in the Medicines List for the medicine; and
(ii) subject to any restriction for the medicine set out in the Medicines List;
and
(b) in relation to a prescribed medicine that is a poison included in Schedule 8, is subject to the condition that an endorsed podiatrist must not use, supply, sell or prescribe the medicine in connection with the treatment of a patient for a period exceeding 7 days.
An endorsed podiatrist is not to be taken to be supplying within the meaning of these regulations if the endorsed podiatrist uses a medicine prescribed under regulation 3G(2) in the lawful practice of his or her profession.
(1) A wholesaler’s licence authorises the licensee to procure, manufacture and supply by wholesale dealing specified poisons at or from specified premises.
(2) A wholesaler’s licence is to be in the form of Form 1 in Appendix A.
(3) A wholesaler’s licence is subject to the condition that any manufacture of a poison under the licence be carried out by —
(a) a specified qualified person or a qualified person authorised under subregulation (4); or
(b) an experienced person acting under the personal supervision of a person referred to in paragraph (a).
(4) A wholesaler’s licence is subject to the condition that any supply of a poison under the licence be carried out by —
(a) a specified qualified person or a qualified person authorised under subregulation (4); or
(b) a specified experienced person or an experienced person authorised under subregulation (4).
(5) If a person specified in a wholesaler’s licence for the purposes of subregulation (3)(a) or (4) —
(a) ceases to work for the licensee; or
(b) in the case of a qualified person specified for the purposes of subregulation (3), is unable to exercise the necessary supervision,
the CEO may in writing authorise another qualified or experienced person (as the case requires) to act in the specified person’s stead.
(6) In this regulation —
A pharmacist shall not sell or supply any poison except at or from a pharmacy described in the licence issued under these regulations as provided in Form 3 in Appendix A.
This licence shall authorise the licensee to procure, and to sell by retail, poisons included in Schedule 2 at the premises described in the licence, and shall be in the Form 5 in Appendix A.
This licence shall authorise the licensee to procure, and to sell by retail, poisons included in Schedule 7 to the Act at the premises described in the licence, and shall be in the Form 6 in Appendix A.
(1) This permit shall, subject to the succeeding provisions of this regulation, authorise the holder to procure from any manufacturer or wholesale supplier specified therein and to supply to certain persons, samples of poisons included in Schedule 2, 3 or 4 and the permit shall be in the Form 6B in Appendix A.
(1a) A permit under this regulation may not be issued in respect of a drug declared to be a
specified drug for the purposes of the Act.(2) A permit under this regulation may be granted only to a person who is —
(a) a representative of a person —
(i) licensed to manufacture poisons or to supply poisons by wholesale dealing; or
(ii) licensed under the provisions of the laws of any other State or Territory of the Commonwealth to manufacture poisons or to supply poisons by wholesale dealing;
and
(b) not less than 21 years of age; and
(c) of good character,
and the holder of a permit shall, for the purposes of these regulations, be known as a detailer.
(3) A permit under this regulation shall contain the name and address of the detailer and the name of each manufacturer or wholesale supplier whom he represents.
(4) Where a detailer ceases to represent a manufacturer or wholesale supplier named in his permit —
(a) the permit shall thereupon cease to authorise the detailer to procure samples from that manufacturer or wholesale supplier or to supply to any person samples procured at any time from that manufacturer or wholesale supplier; and
(b) the detailer shall return to the manufacturer or wholesale supplier any samples that were procured from the manufacturer or wholesale supplier and that are still in the possession or control of the detailer; and
(c) within 7 days of ceasing to represent the manufacturer or wholesale supplier, the detailer shall advise the CEO in writing of the fact and deliver up therewith his permit to the CEO and the CEO shall delete from the permit the name of the manufacturer or wholesale supplier or shall cancel the permit, as the case requires.
(5) A detailer shall not supply a sample to any person who is not —
(a) a medical practitioner; or
(ba) a nurse practitioner; or
(b) a veterinary surgeon; or
(c) a dentist; or
(d) a pharmacist; or
(e) an authorised health practitioner.
(6) A detailer shall not procure, carry or supply a sample —
(a) in the case of an oral contraceptive, for more than 2 months use; or
(b) in any other case, for more than 7 days use,
where the use is in accordance with directions with the sample for maximum dosage, unless the person wishing to be supplied with a larger sample has first made a written request to the manufacturer or wholesale supplier represented by the detailer for the supply of the sample.
(7) Subregulation (6) does not apply to a sample of a proprietary preparation where —
(a) the sample is the smallest size manufactured for sale; and
(b) the CEO, on the recommendation of the Poisons Advisory Committee, has declared such a sample to be a sample to which subregulation (6) does not apply, notwithstanding that the sample may be used —
(i) in the case of an oral contraceptive, for more than 2 months; or
(ii) in any other case, for more than 7 days,
where the use is in accordance with directions with the sample for maximum dosage.
(8) A detailer shall not carry more than —
(a) 25 samples of any single proprietary preparation; or
(b) samples of more than 5 different proprietary preparations,
in a vehicle at any one time.
(9) Where the proper storage of a poison requires that poison be stored under special conditions or at specific temperatures, a detailer shall not store or transport that poison except in a manner which maintains those conditions or temperatures.
(10) Subject to subregulation (11), a detailer shall not cause or permit samples in his possession or control to be stored other than —
(a) on the premises of the manufacturer or wholesale supplier whom he represents; or
(b) at his address as specified in his permit.
(11) A detailer may keep samples in a vehicle while he is actually using that vehicle in the course of his business, but at no other time.
(12) Where pursuant to this regulation samples are stored at an address specified in a detailer’s permit which is not a wholesale supplier’s premises, the detailer shall cause those samples to be stored in a locked cupboard or locked refrigerator and a detailer shall not cause or permit —
(a) more than 100 samples of any single proprietary preparation; or
(b) samples of more than 5 different proprietary preparations,
to be kept at that address at any one time.
(13) A detailer shall not supply a sample unless —
(a) he has received a signed request from a person to whom he is authorised in accordance with subregulation (5) to supply the sample; and
(b) immediately upon supplying the sample, he signs and dates the request form to certify that the sample has been delivered.
(14) A detailer shall keep a record of every sample received or supplied by him and shall preserve all records so kept together with consignment notes, invoices, advice notes and request forms relating thereto, for not less than 2 years.
(15) Upon receiving a written request from the CEO a detailer shall submit all records of samples received and delivered and shall make an account of those samples to the CEO or a person authorised in accordance with section 54 of the Act.
(16) For the purposes of this regulation —
This permit shall authorise the holder to purchase from a manufacturer or wholesale supplier such poisons as are specified in the permit, which shall be in the Form 7 in Appendix A.
This permit shall authorise the holder to purchase from a manufacturer or wholesale supplier such poisons as are specified in the permit, which shall be in the Form 8 in Appendix A.
(1) This permit shall authorise the holder to purchase from a manufacturer or wholesale supplier such poisons as are specified in the permit, which shall be in the Form 8AA in Appendix A.
(2) The permit may not be granted to —
(a) a department or instrumentality of the State or of the Commonwealth; or
(b) a public hospital.
(1) This permit shall authorise the holder to purchase from a manufacturer or wholesale supplier such poisons as are specified in the permit which shall be in the Form 13 in Appendix A and shall not, except in the case of a permit held by a public hospital, authorise the sale of any poison obtained by the permit holder under the authority of the permit.
(2) This permit may be granted only to —
(a) a department or instrumentality of the State or of the Commonwealth; and
(b) a public hospital.
A licence under section 41A of the Act shall be in the form of Form 13A in Appendix A.
(1) The CEO may, in writing, designate a remote area site to be a remote area nursing post for the purposes of these regulations.
(2) The CEO may amend or withdraw a designation under subregulation (1), in writing, at any time.
(1) The CEO may, in writing, designate an area for the purposes of section 23(2)(e) of the Act.
(2) The CEO may amend or withdraw a designation under subregulation (1), in writing, at any time, subject to subregulation (4).
(3) The CEO may not designate an area under subsection (1) until after receiving —
(a) written advice with respect to the proposal to designate the area from the officer of the department who is principally responsible for providing advice on matters related to nursing; and
(b) clinical protocols for the proposed area approved in writing by —
(i) the officer referred to in paragraph (a); and
(ii) the person holding or acting in the office of Chief Health Officer in the department; and
(iii) the person holding or acting in the office known as the Executive Director, Population Health (if any).
(4) The CEO may not amend or withdraw a designation under this section until after receiving written advice with respect to the proposed action from the officer of the department who is principally responsible for providing advice on matters related to nursing.
(1) A person who wishes to apply for a licence under section 24 of the Act or a permit under section 25 of the Act shall lodge with the CEO an application in such form as may be approved by the CEO from time to time for that purpose.
(2) An applicant under this regulation must indicate in the application whether the application is for a period of one year or for 3 years.
(3) The appropriate fees for licences or permits, and renewals of licences or permits, are those set out in Appendix G.
(4) Where the applicant for a licence or permit applies on behalf of a corporate body or firm the application shall contain the name of a natural person who, in respect of the premises named in the application, shall be responsible for carrying out the provisions of the Act and these regulations.
(5) The CEO may only grant an application and issue a licence or permit, or renew a licence or permit, if the application under this regulation is accompanied by the appropriate fee set out in Appendix G.
(1) A person may apply to the CEO for the approval of a needle and syringe programme.
(2) An application referred to in subregulation (1) shall —
(a) be in the form of Form 14 in Appendix A; and
(b) nominate a person to be the coordinator of the programme.
(3) The CEO may by notice in writing require an applicant to provide further information with respect to the application.
(4) An approval of a needle and syringe programme shall —
(a) be given by instrument in writing signed by the CEO; and
(b) clearly identify the programme that is being approved by reference to the activity or activities, and the persons or class of persons engaging in the activity or activities, that constitute the programme; and
(c) specify the period during which the programme is approved.
(5) The CEO is not to approve a needle and syringe programme unless the CEO is satisfied that the coordinator of the programme —
(a) has attained the age of 18 years; and
(b) is a person of good character and repute and is a fit and proper person to coordinate the needle and syringe programme; and
(c) understands his or her duties as the coordinator of the programme.
Where the CEO approves a needle and syringe programme, the CEO is to provide a copy of the instrument of approval to the coordinator of the programme.
The coordinator of an approved needle and syringe programme shall —
(a) maintain a register of all persons who participate in the conduct of the programme; and
(b) ensure that persons who participate in the conduct of the programme understand the requirements of these regulations and are appropriately instructed and trained; and
(c) submit to the CEO before 30 June in each year an annual report on the needle and syringe programme; and
(d) report to the CEO any irregularities that occur in the conduct of the programme.
(1) Where the CEO approves a needle and syringe programme, the CEO may specify in the approval a requirement that the programme only be conducted —
(a) at a specified place or specified places; or
(b) between specified times.
(2) A person shall not conduct, or participate in the conduct of, an approved needle and syringe programme except at a place or between times specified in the approval.
(1) Where the CEO is of the opinion that a person is not a suitable person to participate in the conduct of an approved needle and syringe programme, the CEO may, by notice in writing served on that person, direct the person not to participate in the programme.
(2) A person shall not contravene a direction under subregulation (1).
(1) A person shall not, in the course of the conduct of an approved needle and syringe programme, accept any used hypodermic syringe or used hypodermic needle unless the syringe or needle has been exhausted.
(2) For the purposes of subregulation (1), a hypodermic syringe or a hypodermic needle shall be taken to have been exhausted if it contains no more than the residue of any drug.
(3) A person who, in the course of the conduct of an approved needle and syringe programme, receives any used hypodermic needle or used hypodermic syringe shall immediately place the needle and syringe in a receptacle of a type approved by the CEO and the Commissioner of Police.
A licence or permit shall not be issued to any person under the age of 21 years, unless he is a qualified person approved by the CEO.
A sale of any poison shall not be made by any person other than the licensee or a person, not less than 15 years of age, acting on his behalf.
A licence or permit is not transferable from one person to another.
Provided that —
(a) a licence or permit held in the name of a person on behalf of a firm or corporate body may, on endorsement by the CEO, be transferred into the name of another person on behalf of the firm or corporate body;
(b) the holder of a licence or permit who ceases to carry on or conduct the business or practice to which the licence or permit relates shall within 14 days surrender such licence or permit to the CEO.
The holder of a licence shall keep such licence displayed in a conspicuous place within the premises specified in the licence.
(1) Except as provided by these regulations a person shall not store, supply or transport a poison unless the immediate container in which the poison is stored, supplied or transported complies with Part 2 of the SUSMP.
(2) Except as provided by these regulations a person shall not store, supply or transport a poison unless the container referred to in subregulation (1) bears or has securely affixed to it a label which complies with Part 2 of the SUSMP.
(2a) For the purposes of this regulation, the interpretation provisions of Part 1 of the SUSMP shall be used to interpret Part 2 of the SUSMP as adopted by this regulation.
(1) An immediate container on which the name of any poison is embossed or otherwise permanently marked shall not be used except to contain that poison.
(2) A paper or plastic bag or envelope, or a cardboard box shall not be used as a container for a Schedule 2, 3, 4, 8 or 9 poison whether dispensed or not, unless the poison is also presented to the purchaser in foil or in individually sealed, measured amounts, commonly described as strip packaging, or unless the container is approved by the CEO.
(3) A paper bag shall not be used as the sole container of any poison unless it has been approved by the CEO.
A person shall not sell any food, drink, or condiment, or any drug or medicine for internal use, in a container —
(a) of a description which is not readily distinguishable by sight and touch from a container in which a poison intended for external use may be sold; or
(b) of a like description to that prescribed for a container in which a poison intended for external use may be sold.
(1) Notwithstanding regulation 19, a medicine or preparation containing any poison dispensed or supplied in the course of the professional practice of —
(a) a pharmacist, medical practitioner, nurse practitioner, registered nurse at a remote area nursing post, dentist or authorised heath practitioner, for human internal use shall comply with that regulation if it is labelled in the English language with —
(i) the words “Keep out of reach of children”; and
(ii) the name and strength or amount of each poison in the preparation, or the trade name and strength of the preparation (unless the trade name also uniquely identifies the strength, in which case only the trade name need be given); and
(iii) the name of the patient; and
(iv) a date of dispensing or supply, and a number identifying the prescription or supply which corresponds to —
(I) the entry in the Prescription Book referred to in regulation 36(3)(c), in the case of a pharmacist; or
(II) the patient’s records, in any other case;
and
(v) the name and address of the pharmacy, or medical or dental surgery, or area designated under section 23(2)(e) of the Act, or remote area nursing post, or place of business of an authorised health practitioner, from which it is supplied; and
(vi) the instructions given on the prescription, if dispensed by a pharmacist, or directions for use, if supplied by a medical practitioner, nurse practitioner, registered nurse at a remote area nursing post, pharmacist or dentist; and
(vii) the total quantity contained;
(b) a pharmacist, medical practitioner, nurse practitioner, registered nurse at a remote area nursing post, dentist or authorised health practitioner, for human external use shall comply with that regulation if it is labelled in accordance with paragraph (a), together with the words “Not to be taken”;
(c) a pharmacist or veterinary surgeon, for use on any animal shall comply with that regulation if it is labelled in the English language with —
(i) the words “Keep out of reach of children”; and
(ii) the name and strength or amount of each poison in the preparation, or the trade name and strength of the preparation (unless the trade name also uniquely identifies the strength, in which case only the trade name need be given); and
(iii) the owner’s surname and the species of animal; and
(iv) instructions for the use of that medicine or preparation; and
(v) a date of dispensing, and a number identifying the prescription or supply which corresponds to —
(I) the entry in the Prescription Book referred to in regulation 36(3)(c), in the case of a pharmacist; or
(II) the patient’s records, in the case of a veterinary surgeon;
and
(vi) the name and address of the pharmacy, or veterinary practice, from which it is supplied; and
(vii) the words “For veterinary use only” or “For animal treatment only”, together with the words “For external use only” if the medicine or preparation is not prepared for internal use; and
(viii) the total quantity contained.
(2) Subregulation (1)(a) and (b) do not apply to a medicine or preparation (containing a poison) labelled in accordance with regulation 19, if it is supplied by a medical practitioner or nurse practitioner for the purposes of therapeutic treatment of a patient over a period of not more than 3 days.
(1) A person, whether a pharmacist or otherwise, shall not sell, supply, distribute or dispense a poison for internal human use set out in Appendix K of the SUSMP unless the container immediately containing the poison bears, or has securely affixed to it a label bearing either of the following statements —
“This medicine may cause drowsiness. If affected do not drive a motor vehicle or operate machinery. Avoid alcohol.”; or |
“This medicine may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery.”. |
(2) Subregulation (1) shall not apply to —
(a) a person licensed pursuant to section 24(1)(a) of the Act; and
(b) the supply by a medical practitioner, dentist, pharmacist, nurse practitioner or authorised health practitioner of any poison or substance containing a poison for the purposes of therapeutic treatment to a patient while that patient is hospitalised.
(3) A statement set out in subregulation (1) shall be in letters not less than 1.5 mm in height and in a colour which provides a distinct contrast to the background colour of the container or label on which the statement appears.
(4) In this regulation —
A person shall not include on a label a statement relating to carcinogenicity or teratogenicity in relation to any poison unless the statement in relation to the poison has been approved by the CEO.
The CEO may approve, in writing, a container or label which does not comply with these regulations if, having regard to the nature of the poison and the purpose for which it is to be used, it is unlikely that the interests of safety will be adversely affected by the use of such container or label.
The CEO may, in the interest of safety, suspend or prohibit the use of any form of container or label for the packing or labelling of any poison.
Any person having a poison, other than those specified in regulation 56, in or on any premises for the purpose of sale or use in his profession, business, trade or industry shall keep that poison in such a manner as to preclude contamination of any food, drink or condiment by the poison; and to preclude access to the poison by children.
A person shall not dispose of any poison in any place or manner likely to constitute a risk to the public.
Every person who loses any poison or from whom any poison is stolen shall immediately notify a police officer of such loss or theft.
(1) In this Part and Appendix K —
(2) For the purposes of this Part, an entry is made in a system of electronic prescribing if —
(a) a prescription is issued, amended or cancelled via the system; or
(b) a poison is dispensed in accordance with a prescription issued via the system; or
(c) information is otherwise entered into or retrieved from the system in relation to —
(i) issuing, amending or cancelling a prescription via the system; or
(ii) dispensing a poison in accordance with a prescription issued via the system.
(1) The CEO may approve a system of electronic prescribing if satisfied that the system —
(a) is sufficiently secure; and
(b) is designed so that, to the extent practicable —
(i) for any particular poison — only persons authorised to prescribe that poison can use the system to prescribe the poison; and
(ii) for any particular poison — only a pharmacist authorised to dispense the poison, or an assistant under the direct personal supervision of the pharmacist, can use the system to dispense the poison; and
(iii) a poison dispensed in accordance with a prescription issued via the system is dispensed for the person for whom it was prescribed; and
(iv) a poison dispensed to a person in accordance with a prescription issued via the system is the poison prescribed for the person;
and
(c) complies substantially with the criteria in Appendix K; and
(d) complies with any other criteria the CEO thinks relevant.
(2) A reference in subregulation (1)(b) to a person authorised to prescribe or dispense a particular poison is a reference to a person authorised to do so under the Act.
(3) Before being satisfied that a system of electronic prescribing is sufficiently secure, the CEO must be satisfied that, to the extent practicable —
(a) personal information relating to prescribers, patients of prescribers and pharmacists is protected; and
(b) access to and use of the system is controlled by appropriate procedures; and
(c) only persons permitted to have access to the system according to those procedures can have access to the system; and
(d) every occurrence of —
(i) a prescription being issued or amended via the system; and
(ii) a poison being dispensed in accordance with a prescription issued via the system,
is recorded by the system in a way that cannot be amended or erased.
(4) Subregulation (3) does not limit the matters that the CEO may take into account for the purposes of subregulation (1)(a).
(5) The CEO may approve a component of a system of electronic prescribing if satisfied as to the matters in subregulation (1) in relation to the component, to the extent relevant to the component.
A system of electronic prescribing is not approved while there is no individual who is designated as the administrator of the system by the CEO.
(1) A person must not access an approved electronic prescribing system unless the person —
(a) is permitted to have access to the system according to the procedures that control access to the system; and
(b) gained access according to those procedures.
Penalty: a fine of $5 000.
(2) A person who has an access code for an approved electronic prescribing system must not —
(a) reveal the person’s access code to another person; or
(b) otherwise allow another person to have access to the system unless to do so is in accordance with the procedures that control access to the system.
Penalty: a fine of $5 000.
(3) A person must not make inappropriate use of an approved electronic prescribing system.
Penalty: a fine of $5 000.
(4) An administrator of an approved electronic prescribing system must, to the extent practicable, ensure that —
(a) a person who is permitted to have access to the system in accordance with the procedures that control access to the system is not given more than one access code; and
(b) each person who is responsible to the administrator for the operation and control of the system does not make inappropriate use of the system.
Penalty: a fine of $5 000.
(1) In any proceedings under this Act or the
Misuse of Drugs Act 1981 , if it is proved that the system identifier of a person has been recorded in the system in respect of an entry, then, in the absence of evidence to the contrary, that person is to be taken to have made the entry.(2) Despite anything else in this Part, the administrator must, as soon as is practicable, comply with a written request by a person authorised under section 52A of the Act to make records of the system available to the person.
In this Part —
(1) The CEO may approve the installation of an electronic storage and supply unit on or about premises if satisfied that —
(a) the unit is sufficiently secure; and
(b) the unit is designed so that, to the extent practicable, for any particular poison, only a person who is authorised under the Act to supply or administer the poison can access the unit to remove the poison; and
(c) the installation complies with any other criteria the CEO thinks relevant.
(2) Before being satisfied that an electronic storage and supply unit is sufficiently secure, the CEO must be satisfied that, to the extent practicable —
(a) access to the unit to remove any particular poison from the unit is controlled by appropriate procedures; and
(b) only persons permitted to have access to the unit according to those procedures can have access to the unit for the purpose of removing a particular poison from the unit; and
(c) every occurrence of the removal, or attempted removal, of a poison from the unit is recorded electronically by the unit in a way that cannot be amended or erased.
(3) Subregulation (2) does not limit the matters the CEO may take into account for the purposes of subregulation (1)(a).
(1) A person must not, without the approval of the CEO, install or permit to be installed on or about the person’s premises any electronic storage and supply unit.
Penalty: a fine of $5 000.
(2) A person must not remove a poison from an electronic storage and supply unit unless —
(a) the person is authorised under the Act to supply or administer the poison to another person; and
(b) the person is permitted to have access to the unit according to the procedures that control access to the unit; and
(c) the person has gained access to the unit according to those procedures.
Penalty: a fine of $5 000.
(3) A person who has an access code for an approved electronic storage and supply unit must not —
(a) reveal the person’s access code to another person; or
(b) otherwise allow another person to have access to the unit unless to do so is in accordance with the procedures that control access to the unit.
Penalty: a fine of $5 000.
In any proceedings under this Act or the
A person who sells or supplies any poison to any person who is apparently under 16 years of age commits an offence against these regulations, but this regulation does not apply to sales of pharmaceutical preparations or medicines by persons licensed to sell poisons by retail.
A person shall not —
(a) administer to himself or another person; or
(b) sell or supply for human use,
a medicine or other product which contains a poison and which was prepared for use in animals.
(1) If a paint contains a substance listed in the First, Second or Third Schedule to Appendix I of SUSMP, a person shall not manufacture, sell or use that paint except in accordance with that Appendix.
(2) For the purposes of this regulation the interpretation provisions of Part 1 of the SUSMP shall be used to interpret Appendix I of the SUSMP.
A substance included in Schedule 2 shall not be stored for retail sale in any area or in any manner that allows physical access to that substance by any person other than —
(a) the owner of the business carried on; or
(b) a person employed,
on the premises where it is stored.
(1A) In this regulation —
(a) in the case of pseudoephedrine, a recording system approved in writing by the CEO for the purposes of this regulation; and
(b) for substances other than pseudoephedrine, the Prescription Book referred to in regulation 36(3)(c).
(1) The retail sale of a substance included in Schedule 3 shall only be by way of direct, personal sale by a pharmacist or an intern in pharmacy under the personal supervision of a pharmacist.
(1a) Before a substance included in Schedule 3 is delivered as part of a retail sale, the pharmacist or intern shall take all reasonable steps to ensure that there is a therapeutic need for the substance.
(1b) A pharmacist shall not store in any part of the retail area of premises any of the substances referred to in Appendix J.
(1c) A substance referred to in Appendix J shall only be sold or supplied by direct, personal sale by a pharmacist or an intern in pharmacy under the personal supervision of a pharmacist and, in the case of pseudoephedrine, before it is delivered to the purchaser, the purchaser shall give photographic evidence of his or her identity to the pharmacist or intern, unless the purchaser’s identity is known to the pharmacist or intern.
(2) Before a substance referred to in Appendix J is delivered to a purchaser as part of a retail sale, the pharmacist or intern making the sale shall —
(a) record in a book the following details —
(i) the date of sale;
(ii) the name and address of the purchaser;
(iii) if the person for whom the substance is intended is not the purchaser, the name and address of that other person;
(iv) the name and quantity of the substance supplied;
and
(b) allocate to each sale a unique identification number or alpha‑numerical code, and record that number or code in the register; and
(c) label the product containing the substance with —
(i) the name and address of the pharmacy; and
(ii) the number or code allocated under paragraph (b).
(3) A book must be available for inspection by an authorised officer at all reasonable times.
(4) The seller shall retain the records required to be made under this regulation for a period of at least 2 years.
A substance included in Schedule 3 shall not be stored in a pharmacy in any area or in any manner that allows physical access to that substance by any person other than a person who is a member of the staff of the pharmacy.
(1) Subject to subregulations (2) and (3), a substance included in Schedule 3 shall not be advertised except in a bona fide professional or trade journal or other publication intended for circulation only within the medical, veterinary, dental or pharmaceutical professions or the wholesale and manufacturing drug trade.
(2) A substance both included in Schedule 3 and listed in Appendix H of SUSMP may be advertised by its brand name or its approved name.
(3) A substance included in Schedule 3 may be advertised if the substance is in a pregnancy testing kit.
(4) In this regulation —
A substance included in Schedule 4 shall not be advertised except in a publication that is normally sold or intended for sale or circulation only among —
(a) persons of the kind referred to in section 23(2) of the Act; or
(b) persons who are holders of licences granted under section 24(1)(a), (b) or (c) of the Act.
(1) Subject to the Act and these regulations, a person shall not sell or supply a poison included in Schedule 4 to any person unless —
(a) he or she —
(i) is satisfied that the person to whom the poison is sold or supplied is authorised under regulation 40(1) or (1AB) to procure the poison; and
(ii) receives from that person a written order in accordance with regulation 40(1a) or makes a record under regulation 41B;
or
(b) the person to whom the poison is sold or supplied is the person (or an agent of the person) in respect of whom a prescription for the poison was issued by a medical practitioner, nurse practitioner, dentist, authorised health practitioner or veterinary surgeon prescribing the poison according to the requirements of these regulations; or
(c) satisfied that the person to whom the poison is sold or supplied is under medical treatment with the poison and requires emergency treatment with the poison and does not sell or supply to that person more than —
(i) 3 days medication of the poison; or
(ii) where the poison is supplied in prepacked individual packs, one individual standard pack;
or
(da) in the case of a poison that is referred to in the
National Health (Continued Dispensing) Determination 2012 (Commonwealth) Schedule 1 as in force on 1 July 2012 —(i) the poison is sold or supplied by a pharmacist; and
(ii) the pharmacist selling or supplying the poison is satisfied on reasonable grounds that —
(I) the person to whom the poison is sold or supplied (the
patient ) is under regular medical treatment with the poison; and(II) it is not practical for the patient to obtain a prescription for the poison in sufficient time to allow for the treatment to continue uninterrupted; and
(III) the patient has not been supplied with the poison without a prescription in the period of 12 months preceding the day on which the poison is sold or supplied;
and
(iii) the quantity of the poison sold or supplied to the patient is not more than that required to provide 30 days treatment; and
(iv) the pharmacist notifies the person who is medically treating the patient with the poison within 24 hours of the sale or supply;
or
(d) he or she is a registered nurse working at a remote area nursing post and he or she supplies a poison, not being a psychoactive poison —
(i) in accordance with regulation 36(1)(c)(i); or
(ii) for the treatment of an acute medical condition in compliance with the written standing orders of a medical practitioner which have been approved in writing by the CEO; or
(iii) for the treatment of an acute medical condition in compliance with oral instructions of a medical practitioner or nurse practitioner for that particular patient.
(1a) A person who has received a written order under subregulation (1)(a)(ii) shall keep that order for at least 2 years from the time he or she received it and produce it at any time during the 2 years from the time he or she received it when required to do so by the Chief Health Officer.
(2) A medical practitioner, nurse practitioner, pharmacist, authorised health practitioner or veterinary surgeon or an assistant under the direct personal supervision of a medical practitioner, nurse practitioner, pharmacist, authorised health practitioner or veterinary surgeon shall be the only person who shall dispense a poison included in Schedule 4.
(3) The following conditions shall be observed by persons dispensing such prescriptions —
(a) the prescription shall not be dispensed more than the maximum number of times indicated by it, and on each occasion upon which it is dispensed the dispenser shall —
(i) in the case of a prescription that is not issued electronically — stamp or mark the prescription to show clearly the date upon which it is dispensed and the name and address of the pharmacy at which it is dispensed; and
(ii) in the case of a prescription that is issued electronically — indicate the date upon which it is dispensed and the name and address of the pharmacy at which it is dispensed using the means provided by the approved electronic prescribing system;
(b) the person who dispenses a prescription which does not clearly indicate the maximum number of times it is to be dispensed, or which has reached the last occasion upon which it may be dispensed according to the maximum indicated by it, shall —
(i) in the case of a prescription that is not issued electronically — write in ink, stamp or mark in legible letters across the prescription the word “cancelled”; and
(ii) in the case of a prescription that is issued electronically — cancel the prescription using the means provided by the approved electronic prescribing system;
(c) (i) for the purposes of this paragraph —
(I) handwritten records in a bound book with sequentially numbered pages; or
(II) computer records on disk or tape that can be displayed and from which printed copies of the records can be produced on demand; or
(III) microfilm, microfiche, or any other photographic systems in logical sequence and retrievable form; or
(IV) client record cards, which include the details set out in a prescription; or
(V) alternative recording methods which have been specifically and individually approved in writing by the CEO for the purposes of this paragraph,
are deemed to be the Prescription Book; and
(ii)beforethepoisonishandedtothepurchaserthefollowingdetailsfromtheprescriptionshallbeenteredintothePrescription Book —
the name and quantity of the poison, the direction for use (if applicable), the date of issue of the prescription, the name and address of the patient, the name and address, or the name and identifying initials, of the prescriber, the date of dispensing the prescription, and the entry shall be given an identifying letter or number or combination of letter and number;
and
(iii) in the event of the dispensing of a repeated prescription an annotation of this fact showing the date of the repeat on the original entry in the Prescription Book shall be sufficient compliance with this regulation; and
(iv) the label on the bottle or package containing the poison shall be marked with the identifying letter or number of the prescription as appearing in the Prescription Book; and
(v) the Prescription Book shall be kept at the place at which the poison included in Schedule 4 was dispensed for at least 2 years and shall be produced on demand to any person authorised in that behalf under the Act or these regulations;
(d) a prescription shall not be dispensed if it is —
(i) cancelled; or
(ii) more than 12 months old;
(e) a prescription which is illegible or defaced, or appears to have been altered or which appears to be for the purpose of enabling some unauthorised person to obtain a poison included in Schedule 4, or which does not appear to be genuine, shall not be dispensed;
(f) a pharmacist given a prescription referred to in paragraph (e) shall forthwith inform the CEO of the relevant circumstances and the reasons for his refusal to dispense the prescription, and, in the case of a prescription that was not issued electronically, retain it.
(4A) A pharmacist who sells or supplies a poison in Schedule 4 under subregulation (1)(da) must enter the following information into the Prescription Book referred to in subregulation (3)(c) —
(a) the name and quantity of the poison;
(b) the direction for use (if applicable);
(c) the date of sale or supply of the poison;
(d) the name and address of the patient;
(e) the name and identifying initials of the person who is medically treating the patient with the poison;
(f) an identifying letter or combination of letter and number for the entry.
(4) The following conditions shall be observed by persons supplying poisons included in Schedule 4 under subregulation (1)(d) —
(a) the supply shall be recorded in the client record cards of the remote area nursing post and the record cards kept for a minimum of 2 years following the last entry in those records; and
(b) the poisons shall be labelled in accordance with regulation 21(1)(a) or 21(1)(b).
(1) In this regulation —
(a) operates outside the metropolitan region (as defined in section 6 of the
Metropolitan Region Town Planning Scheme Act 1959 3 ); and(b) has been approved by the CEO for the purposes of this regulation;
(a) if the poison is supplied in prepacked individual packs, one individual standard pack; or
(b) if the poison is a liquid, the smallest pack of the poison available from the manufacturer; or
(c) otherwise, not more than 3 days medication of the poison;
(2) A registered nurse at an approved health service may give an approved starter pack to a patient, other than an in‑patient, at the health service if orally instructed to do so by a medical practitioner or nurse practitioner, who need not be present at the health service.
(3) Before giving an approved starter pack to a patient a registered nurse must —
(a) ensure that the approved starter pack is labelled in accordance with subregulation (8); and
(b) record the details of the provision of the approved starter pack in accordance with subregulation (10).
(4) A medical practitioner or nurse practitioner must not give a starter pack instruction unless satisfied that —
(a) the patient has an acute medical condition; and
(b) there is no other medical practitioner or nurse practitioner at the health service who could reasonably attend to the patient in person; and
(c) the distance from the health service to the nearest pharmacy that is open is more than 25 km.
(5) For the purposes of subregulation (4), a medical practitioner or nurse practitioner may rely on information provided by the registered nurse as to the patient’s condition, the availability of other medical practitioners or nurse practitioners and the location of the nearest open pharmacy.
(6) Within 72 hours of giving a starter pack instruction a medical practitioner or nurse practitioner must give to the registered nurse, or another registered nurse at the health service, signed, written confirmation of the instruction including —
(a) the name of the medical practitioner or nurse practitioner; and
(b) the name of the registered nurse to whom the starter pack instruction was given; and
(c) the name of the patient; and
(d) the date and time when the instruction was given; and
(e) details of the approved starter pack; and
(f) any relevant directions for use that were to be given to the patient; and
(g) any other information that the medical practitioner or nurse practitioner considers relevant.
(7) The person in charge of an approved health service must —
(a) keep all written confirmations given under subregulation (6) to registered nurses at the health service for at least 2 years; and
(b) produce them on demand to any person authorised under the Act to demand production of such records.
(8) An approved starter pack must be labelled in English with —
(a) the words “Keep out of reach of children”; and
(b) the name of the patient; and
(c) the name and address of the health service; and
(d) in relation to each poison in the approved starter pack —
(i) the approved name and strength or amount of the poison; or
(ii) if the brand name uniquely identifies the strength of the poison, that brand name;
and
(e) the total quantity of medication contained in the approved starter pack; and
(f) the date on which the approved starter pack was given to the patient; and
(g) any directions for use given by the medical practitioner or nurse practitioner; and
(h) the number referred to in subregulation (10)(f) identifying the relevant entry in the health service’s Starter Pack Supply Book; and
(i) any relevant cautionary or advisory statements set out in Appendix K to the SUSMP.
(9) The person in charge of an approved health service must —
(a) maintain a Starter Pack Supply Book for the health service consisting of —
(i) handwritten records in a bound book with sequentially numbered pages; or
(ii) records kept in another manner which has been specifically and individually approved in writing by the CEO for the purposes of this paragraph;
and
(b) keep the Starter Pack Supply Book for at least 2 years after the last entry is made in it; and
(c) produce the Starter Pack Supply Book on demand to any person authorised under the Act to demand production of such records.
(10) Before giving an approved starter pack to a patient a registered nurse must record the following information in the health service’s Starter Pack Supply Book —
(a) the name and address of the patient; and
(b) in relation to each poison in the approved starter pack —
(i) the approved name and strength or amount of the poison; or
(ii) if the brand name uniquely identifies the strength of the poison, that brand name;
and
(c) the date and time at which the approved starter pack is to be given to the patient; and
(d) the name of the medical practitioner or nurse practitioner; and
(e) any directions for use given by the medical practitioner or nurse practitioner; and
(f) a unique number identifying the entry in the Book; and
(g) the registered nurse’s name and signature.
(1) In this regulation —
(a) is provided in the metropolitan region; and
(b) responds to psychiatric emergencies in the community; and
(c) is designated by the CEO for the purposes of this definition;
(a) if the poison is supplied in prepacked individual packs — is one individual standard pack; or
(b) if the poison is a liquid — is the smallest pack of the poison available from the manufacturer; or
(c) otherwise — does not exceed 3 days worth of medication of the poison;
(a) is provided outside the metropolitan region; and
(b) responds to psychiatric emergencies in the community; and
(c) is approved by the CEO for the purposes of this definition;
(2) A team registered nurse may give a psychiatric emergency pack to a patient, other than an in‑patient, if instructed to do so by a team psychiatrist or a team medical practitioner, who need not be present with the nurse at the time of giving the instruction.
(3) The instruction may be given orally.
(4) The psychiatrist or medical practitioner must not give the instruction unless satisfied that the patient is in need of urgent psychiatric intervention and it is not practical for the patient to obtain the medication contained in the pack in any other way.
(5) For the purposes of subregulation (4), the psychiatrist or medical practitioner may rely on the information given by the nurse about the patient’s condition.
(6) Before giving the psychiatric emergency pack to the patient the nurse must —
(a) ensure that the pack has been labelled in accordance with subregulation (9); and
(b) record in the Emergency Pack Supply Book the information required by subregulation (11).
(7) Within 72 hours of giving the instruction the psychiatrist or medical practitioner must give the nurse, or another team member, signed, written confirmation of the instruction including —
(a) the name of the psychiatrist or medical practitioner; and
(b) the name of the nurse to whom the instruction was given; and
(c) the name of the patient; and
(d) the date and time when the instruction was given; and
(e) details of the psychiatric emergency pack; and
(f) any directions for use that were to be given to the patient; and
(g) any other information that the psychiatrist or medical practitioner considers relevant.
(8) A person in charge of a Community Emergency Response Team or a Rural Community Mental Health Team must —
(a) keep all written confirmations given under subregulation (7) for at least 2 years; and
(b) produce them on demand to any person authorised under the Act to demand production of such records.
(9) A psychiatric emergency pack must be labelled in English with —
(a) the words “keep out of reach of children”; and
(b) the name of the patient; and
(c) the name and address of the Community Emergency Response Team or the Rural Community Mental Health Team; and
(d) in relation to the poison in the psychiatric emergency pack —
(i) the approved name and strength or amount of the poison; or
(ii) if the brand name uniquely identifies the strength of the poison — that brand name;
and
(e) the total quantity of each medication contained in the psychiatric emergency pack; and
(f) the date on which the psychiatric emergency pack was given to the patient; and
(g) any directions for use given by the psychiatrist or medical practitioner; and
(h) the number referred to in subregulation (11)(f) identifying the relevant entry in the Emergency Pack Supply Book; and
(i) any relevant cautionary or advisory statements set out in Appendix K to the SUSMP.
(10) A person in charge of a Community Emergency Response Team or a Rural Community Mental Health Team must —
(a) maintain an Emergency Pack Supply Book for that Team consisting of handwritten records in a book with sequentially numbered pages; and
(b) keep the Emergency Pack Supply Book for at least 2 years after the last entry is made in it; and
(c) produce the Emergency Pack Supply Book on demand to any person authorised under the Act to demand production of such records.
(11) The information to be recorded in the Emergency Pack Supply Book is —
(a) the name and address of the patient; and
(b) in relation to the poison in the psychiatric emergency pack —
(i) the approved name and strength or amount of the poison; or
(ii) if the brand name uniquely identifies the strength of the poison — that brand name;
and
(c) the date and time at which the psychiatric emergency pack is to be given to the patient; and
(d) the name of the psychiatrist or medical practitioner who gave the instruction; and
(e) any directions for use given by the psychiatrist or medical practitioner; and
(f) a unique number identifying the entry in the Book; and
(g) the nurse’s name and signature.
(1) A pharmacist to whom a substance included in Schedule 4 is supplied shall not store it, or expose or offer it for sale, in any portion of a pharmacy to which persons other than members of the staff of the pharmacy have access.
(2) Subject to subregulation (3), a medical practitioner, dentist, nurse practitioner, authorised health practitioner, podiatrist or veterinary surgeon to whom a substance included in Schedule 4 is supplied shall store it in a container, cupboard or room —
(a) at the medical practitioner’s, dentist’s, nurse practitioner’s, authorised health practitioner’s, podiatrist’s or veterinary surgeon’s usual place of practice; and
(b) that is kept locked; and
(c) access to which is available only to the medical practitioner, dentist, nurse practitioner, authorised health practitioner, podiatrist or veterinary surgeon and persons under his or her personal supervision.
(3) A medical practitioner, dentist, nurse practitioner, authorised health practitioner, podiatrist or veterinary surgeon may store substances included in Schedule 4 other than in accordance with subregulation (2) if —
(a) they are emergency supplies; and
(b) the medical practitioner, dentist, nurse practitioner, authorised health practitioner, podiatrist or veterinary surgeon has them in his or her actual possession for the purpose of attending patients at places other than at his or her usual place of practice.
(4) In subregulation (3) —
(a) in the case of a medical practitioner — the substances described as “Emergency Drug (Doctor’s Bag) Supplies” in the document “Schedule of Pharmaceutical Benefits”, as published from time to time by the Commonwealth Government for the purposes of Part VII of the
National Health Act 1953 of the Commonwealth; or(b) in the case of a nurse practitioner — the substances identified in a clinical protocol for the designated area where the nurse practitioner practices as substances that may be used by the nurse practitioner at places other than at his or her usual place of practice; or
(c) in the case of any other category of person referred to in subregulation (3) — the substances that are ordinarily carried by persons of that category who are attending patients at places other than their usual place of practice.
(1) A medical practitioner, nurse practitioner, dentist, midwife, optometrist, podiatrist or veterinary surgeon is to record in his or her client record cards every occasion on which he or she —
(a) supplies a substance included in Schedule 4 to a person; or
(b) administers a substance included in Schedule 4 to a person or animal.
(2) A record required to be made under subregulation (1) is to include —
(a) the name, strength and quantity of the substance supplied or administered; and
(b) the name and address of the person to whom the substance was supplied or administered, or of the owner of the animal to which the substance was administered; and
(c) the date on which the substance was supplied or administered.
(3) A record required to be made under regulation (1) must be —
(a) kept for at least 2 years from the date on which the substance was supplied or administered; and
(b) made available for inspection on request by an authorised officer.
(1) Under section 21A of the Act, H1N1 Pandemic Influenza Vaccine is exempt from the operation of sections 23(1) and 32(c) of the Act and regulations 33 and 36 —
(a) if the vaccine is administered to a person by a registered nurse in the course of his or her employment —
(i) in the Department (as defined in the
Health Services Act 2016 section 6); or(ii) in a health service provider (as defined in the
Health Services Act 2016 section 6);
and
(b) to the extent, and only to the extent, that those provisions relate to the supply of a poison.
(2) A registered nurse is to make a record in a form approved by the CEO of every occasion on which he or she administers H1N1 Pandemic Influenza Vaccine to a person.
(3) A record required to be made under subregulation (2) is to include —
(a) the name, quantity and batch number of the vaccine administered;
(b) the name, address, date of birth and gender of the person to whom the vaccine was administered;
(c) the date on which the vaccine was administered;
(d) the registered nurse’s name and signature.
(4) The records must be kept for at least 2 years from the date on which the vaccine was administered.
(1) Under section 21A of the Act, a Schedule 4 poison is exempt from the operation of sections 23(1) and 32(c) of the Act and regulations 33 and 36 if —
(a) it is contained in a vaccine listed in Appendix B; and
(b) the vaccine is administered to a person by a registered nurse or a registered midwife in the course of the registered nurse’s or the registered midwife’s employment —
(i) in the Department (as defined in the
Health Services Act 2016 section 6); or(ii) in a health service provider (as defined in the
Health Services Act 2016 section 6);(iii) by a local government; or
(iv) by the Aboriginal Health Council of
Western Australia (ACN 114 220 478); or(v) in a health service that is a member of the Aboriginal Health Council of Western Australia (ACN 114 220 478); or
(vi) in the Department (as defined in the
Prisons Act 1981 section 3(1));
and
(c) the vaccine is administered in accordance with the code for the administration of the vaccine approved by the CEO and published on the department’s website.
Note:
The department’s website address is < label="(2)">
The exemption in subregulation (1) applies only to the extent that the provisions in respect of which it applies relate to the supply of a poison.
(1) Under section 21A of the Act, a Schedule 4 poison described in an item in the Table is exempt from the operation of sections 23(1) and 32(c) of the Act and regulations 33 and 36 if —
(a) the poison is administered for treatment of a condition referred to in the same item of the Table through a public health programme approved by the CEO; and
(b) the poison is administered to a person by a registered nurse who has qualifications approved by the CEO for the purposes of the public health programme; and
(c) the poison is administered in accordance with a code for the administration of the poison approved by the CEO in connection with the public health programme and published on the department’s website.
Note:
The department’s website address is < of poisons
1.
azithromycin, amoxicillin and probenecid contained in a single oral dose pack
sexually transmitted disease
2.
azithromycin
trachoma
(2) The exemption in subregulation (1) applies only to the extent that the provisions in respect of which it applies relate to the supply of a poison.
(1) A prescription for a poison included in Schedule 4 shall comply with the following conditions —
(a) it shall include —
(i) the name and address of the prescriber; and
(ii) the name and address of the patient; and
(iii) the name and quantity of the substance; and
(iv) directions for use (if necessary); and
(v) the date on which it is issued; and
(vi) the maximum number of times it may be repeated, if any, and (where applicable) the intervals at which it may be repeated;
(b) it shall be issued in a manner provided for in subregulation (1A) or (1B);
(c) a prescription issued by a dentist shall be for dental purposes only and shall indicate that and a prescription issued by a veterinary surgeon shall be for veterinary use only and shall include the words “For veterinary use only” or “For animal treatment only”;
(da) a prescription issued by an endorsed optometrist must include the words “For optometrical treatment only”;
(db) a prescription issued by an endorsed podiatrist must include the words “For podiatric treatment only”;
(d) if a prescription contains an unusual dose the prescriber shall indicate that such a dose is intended by —
(i) in the case of a prescription that is not issued electronically — underlining that part of the prescription and initialling the same in the margin; and
(ii) in the case of a prescription that is issued electronically — the means provided by the approved electronic prescribing system;
(e) a prescription shall not bear the impression of a rubber stamp or other such contrivance in lieu of the written signature of the medical practitioner, nurse practitioner, dentist or veterinary surgeon by whom it has been written;
(f) a prescription shall not be written in cipher.
(1A) A prescription that is issued electronically shall be issued via an approved electronic prescribing system.
(1B) A prescription that is not issued electronically shall be either —
(a) written in ink in the prescriber’s own handwriting; or
(b) processed on a computer program that —
(i) complies with the criteria specified in Appendix L; or
(ii) is recommended by the Poisons Advisory Committee and approved in writing by the CEO.
The prescription shall be signed by the prescriber in his or her own handwriting.
(2) With the written approval of the CEO a medical practitioner, nurse practitioner, dentist, authorised health practitioner or veterinary surgeon may issue a typewritten prescription where the CEO is satisfied that by reason of physical infirmity the prescriber is unable to write legibly in his or her own handwriting but in that case the prescriber shall sign the prescription with his or her usual signature.
(1) In this regulation —
(2) An NIMC for a patient who is discharged from a public hospital is to be taken to be a prescription for a Schedule 4 poison that complies with regulation 37 for the purposes of dispensing the Schedule 4 poison at the public hospital on the discharge of the patient if —
(a) all the details in respect of the patient required by the NIMC have been completed; and
(b) a medical practitioner, nurse practitioner or authorised health practitioner has completed, in ink in his or her own hand writing, all the details in respect of the Schedule 4 poison required by the NIMC; and
(c) a medical practitioner, nurse practitioner or authorised health practitioner has written, in ink, an authorisation on the NIMC for the Schedule 4 poison to be dispensed for discharge, and dated and signed the authorisation.
(1) In this regulation —
(2) An NRMC for a person who is a care recipient in a residential care facility is to be taken to be a prescription for a Schedule 4 poison that complies with regulation 37 for the purposes of dispensing the poison for the use of the person if —
(a) all the details in respect of the person required by the NRMC have been completed; and
(b) a medical practitioner, nurse practitioner or authorised health practitioner has completed, in ink in his or her own hand writing all the details in respect of the Schedule 4 poison required by the NRMC.
Where a medical practitioner, nurse practitioner, dentist, authorised health practitioner or veterinary surgeon in a case of emergency orally or by telephone or other electronic means directs the dispensing of a poison included in Schedule 4, he shall forthwith write a prescription complying with the conditions prescribed in regulation 37, mark such prescription to show that it has been given as a confirmation of instructions given by him orally or by telephone or other electronic means, and despatch such prescription within 24 hours to the person to whom the instructions were given.
(1) Subject to subregulation (2) a person, other than a medical practitioner, nurse practitioner, dentist or authorised health practitioner, shall not administer a poison included in Schedule 4 to a patient in a hospital unless the administration of the poison is authorised in writing on the medication chart of the patient by a medical practitioner, nurse practitioner, dentist or an authorised health practitioner.
(2) A medical practitioner, nurse practitioner, dentist or authorised health practitioner may verbally authorise the administration of a poison included in Schedule 4 and shall within 24 hours of so doing note such authorisation in writing on the medication chart of the patient.
Clomiphene or cyclofenil or a substance containing clomiphene or cyclofenil and other substances specifically prepared to stimulate ovulation shall not be prescribed except —
(a) by a gynaecologist or obstetrician; or
(b) by any other medical practitioner, if authorised in writing by the CEO; or
(c) by a veterinary surgeon for the purpose of veterinary trials under the direction of a veterinary surgeon.
(1) Etretinate or acitretin or a substance containing etretinate or acitretin shall not be prescribed except by a physician or dermatologist.
(1a) Where etretinate or acitretin or a substance containing etretinate or acitretin is supplied in accordance with a prescription under subregulation (1) the supplier shall ensure that the container in which the etretinate or acitretin or the substance containing etretinate or acitretin is supplied, is labelled with a warning in the following words, or other words having the same effect —
“WARNING — CAUSES BIRTH DEFECTS”.
(2) A physician or dermatologist who prescribes etretinate or acitretin or a substance containing etretinate or acitretin shall ensure that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant for a period of 24 months after completion of the treatment.
Cloprostenol, dinoprost, dinoprostone, fenprostalene, fluprostenol, prostianol or a substance containing any of those prostaglandins shall not be prescribed except —
(a) by a veterinary surgeon for use in the treatment of animals; or
(b) in the case of dinoprost or dinoprostone or a substance containing dinoprost or dinoprostone —
(i) by a physician, gynaecologist or obstetrician; or
(ii) by any other medical practitioner, if authorised in writing by the CEO.
(1) Isotretinoin or a substance containing isotretinoin shall not be prescribed except by a physician or dermatologist.
(1a) Where isotretinoin or a substance containing isotretinoin is supplied in accordance with a prescription under subregulation (1) the supplier shall ensure that the container in which the isotretinoin or the substance containing isotretinoin is supplied, is labelled with a warning in the following words, or other words having the same effect —
“WARNING — CAUSES BIRTH DEFECTS”.
(2) A physician or dermatologist who prescribes isotretinoin or a substance containing isotretinoin shall ensure that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant for a period of one month after completion of the treatment.
(1) Thalidomide or a substance containing thalidomide shall not be prescribed except by a physician or dermatologist.
(2) Where thalidomide or a substance containing thalidomide is supplied in accordance with a prescription under subregulation (1) the supplier shall ensure that the container in which the thalidomide or the substance containing thalidomide is supplied, is labelled with a warning in the following words, or other words having the same effect —
“WARNING — CAUSES BIRTH DEFECTS”.
(3) A physician or dermatologist who prescribes thalidomide or a substance containing thalidomide shall ensure that the possibility of pregnancy has been excluded prior to the commencement of treatment and that the patient is informed that she must not become pregnant for a period of one month after completion of treatment.
Chloramphenicol or substances containing chloramphenicol shall not be prescribed except —
(a) by a medical practitioner or nurse practitioner for human use; or
(ba) by an endorsed optometrist as a topical ocular preparation for human use; or
(b) by a veterinary surgeon for use in or on an animal not used for meat, edible offal, egg or milk production.
Follicular stimulating hormone, luteinising hormone or a substance containing follicular stimulating hormone or luteinising hormone shall not be prescribed except —
(a) by a physician, gynaecologist or obstetrician; or
(b) by any other medical practitioner, if authorised in writing by the CEO; or
(c) by a veterinary surgeon for the purpose of veterinary trials under the direction of a veterinary surgeon.
Carnidazole or a substance containing carnidazole shall not be prescribed except by a veterinary surgeon for use in the treatment of pigeons.
Oxolinic acid or any substance containing oxolinic acid shall not be prescribed except by a veterinary surgeon for use in the treatment of fish.
Clozapine or a substance containing clozapine shall not be prescribed except —
(a) by a psychiatrist; or
(b) by any other medical practitioner authorised in writing by the CEO.
The nitrofuran derivatives included in Schedule 4 and listed in the Table to this regulation, or a substance containing any of those poisons, shall not be prescribed except —
(a) by a medical practitioner or nurse practitioner for human use; or
(ba) in the case of nitrofurantoin, by an endorsed midwife for human use; or
(b) by a veterinary surgeon for use in the feeding or treatment of an animal not used for meat, edible offal, egg or milk production.
Furazolidone |
Nifursol |
Nitrofuran |
Nitrofurantoin |
Nitrofurazone. |
(1) Bosentan or a substance containing bosentan shall not be prescribed except —
(a) by a physician; or
(b) by any other medical practitioner authorised in writing by the CEO.
(2) Where bosentan or a substance containing bosentan is supplied in accordance with a prescription under subregulation (1) the supplier shall ensure that the container in which the bosentan or the substance containing bosentan is supplied is labelled with a warning in the following words, or other words having the same effect —
“WARNING — CAUSES BIRTH DEFECTS”.
(3) A physician, or other medical practitioner, who prescribes bosentan or a substance containing bosentan shall ensure that the possibility of pregnancy has been excluded prior to the commencement of treatment and that the patient is informed that she must not become pregnant during or for a period of 3 months after completion of treatment.
Teriparatide or a substance containing teriparatide shall not be prescribed except —
(a) by a physician, a rheumatologist, an immunologist, an endocrinologist or a geriatrician; or
(b) by any other medical practitioner authorised in writing by the CEO.
Despite regulation 36(1), a pharmacist is authorised to sell or supply a poison included in Schedule 4 to a person without a prescription if —
(a) the poison is contained in an influenza virus vaccine; and
(b) the vaccine is administered to the person by the pharmacist; and
(c) there is compliance with each provision of the Pharmacist Vaccination Code published under the authority of the CEO on the department’s website.
Note:
The department’s website address is < inserted in Gazette 12 Dec 2014 p. 4714‑15.]
(1) Notwithstanding the provisions of regulation 36 a pharmacist is authorised to supply for veterinary use a poison included in Schedule 4 listed in Appendix H without a prescription where —
(a) the purchaser satisfies such pharmacist that it is not reasonably practicable for him to obtain such a prescription; and
(b) the name and address of the purchaser, date of supply, form and quantity of poison supplied, species of animal and number of animals to be treated, and a descriptive name of the disease for which the animals are to be treated, are entered in a register of poisons; and
(c) the quantity of poisons supplied is not greater than is required to provide 72 hours of therapeutic treatment according to the directions for normal dosage with the poison, or in the case of a pre‑packed proprietary brand the smallest size manufactured for sale of the proprietary brand which provides 72 hours treatment; and
(d) the pharmacist provides adequate written instructions for the use of the poison.
[(2) deleted]
(1) Notwithstanding any other provision of these regulations a stockfeed manufacturer holding an appropriate permit under subregulation (3) may sell by retail to any person producing a written order therefor signed by a veterinary surgeon, a mixture of stockfeed with any poison included in Schedule 4 being an antibiotic or sulphonamide, in such quantity and of such composition as is specified in the order.
(2) The signed order shall be cancelled by the stockfeed manufacturer and retained by him for not less than 2 years after the sale, and upon request shall be produced for inspection to an authorised officer.
(3) A stockfeed manufacturer who wishes to sell by retail mixtures pursuant to subregulation (1) may apply to the CEO for, and at the discretion of the CEO be granted, a permit in Form 11AA in Appendix A, specifying the poisons included in Schedule 4 that may be contained in such mixtures, and any limits as to the quantity or composition of such mixtures that may be sold.
(4) The provisions of section 23 of the Act do not apply to a sale by a stockfeed manufacturer pursuant to and in accordance with this regulation or to the preparation of a mixture of stockfeed for the purposes of such sale.
(1) The master of a certificated commercial vessel is authorised to procure and be in possession of any poison included in Schedule 4 that is necessary to complete the equipment of the vessel in order to comply with the requirements of the
Western Australian Marine Act 1982 .(2) The holder of an appropriate licence, or any other authorised person, may supply a poison included in Schedule 4 on receipt of a written order, signed by the master of the certificated commercial vessel, certifying that the poison is necessary to complete the equipment of the vessel in order to comply with the applicable requirements of subregulation (1).
(3) The written order referred to in subregulation (2) must contain all of the following information —
(a) the date of the order;
(b) the name of the certificated commercial vessel;
(c) the machinery and hull number;
(d) the name, address and signature of the master of the vessel;
(e) the quantity, form and strength of the poison ordered.
(4) The master of the certificated commercial vessel must ensure that —
(a) so far as is practicable, the poisons supplied under subregulation (2) are stored in a manner that prevents their theft, loss or unauthorised use; and
(b) a record is kept of all the poisons stored aboard the vessel.
(5) When a medical practitioner authorises the administration of one of the poisons to a person on board the certificated commercial vessel, the master of the vessel must ensure that a record is kept of all of the following information —
(a) the date on which the poison was administered;
(b) the poison being administered, the strength of the poison and the quantity that has been administered;
(c) the name of the person to whom the poison has been administered;
(d) the name and address of the medical practitioner who authorised the administration of the poison.
(1) The owner of a racing yacht is authorised to procure and be in possession of any poison included in Schedule 4 that is necessary to complete the equipment of the yacht in order to comply with the requirements of the rules known as the “Racing Rules of Sailing” made by Yachting Australia Incorporated.
(2) The holder of an appropriate licence, or any other authorised person, may supply a poison included in Schedule 4 on receipt of a written order, signed by the owner of the racing yacht, certifying that the poison is necessary to complete the equipment of the yacht in order to comply with the applicable requirements of subregulation (1).
(3) The written order referred to in subregulation (2) must contain all of the following information —
(a) the date of the order;
(b) the name of the racing yacht;
(c) the registration number of the racing yacht;
(d) the name of the yacht club organising the race;
(e) the name, address and signature of the owner of the yacht;
(f) the quantity, form and strength of the poison ordered.
(4) The owner of the racing yacht must ensure that —
(a) so far as is practicable, the poisons supplied under subregulation (2) are stored in a manner that prevents their theft, loss or unauthorised use; and
(b) a record is kept of all the poisons stored aboard the yacht.
(5) When a medical practitioner authorises the administration of one of the poisons to a person on board the racing yacht, the skipper of the yacht must ensure that a record is kept of all of the following information —
(a) the date on which the poison was administered;
(b) the poison being administered, the strength of the poison and the quantity that has been administered;
(c) the name of the person to whom the poison has been administered;
(d) the name and address of the medical practitioner who authorised the administration of the poison.
(1) The master of a ship other than a certificated commercial vessel or a racing yacht is authorised to procure and be in possession of any poison included in Schedule 4 that is necessary to complete the equipment of the ship in order to comply with the requirements of —
(a) if the ship is registered in
Australia —(i) section 125 of the
Navigation Act 1912 4 of the Commonwealth; or(ii) the navigation authority of any State of Australia;
or
(b) if the ship is not registered in
Australia —(i) a law applying to ships in the country in which the ship is registered; or
(ii) the “
International Medical Guide for Ships ” (2nd. Edition), as published by the World Health Organization.
(2) The holder of an appropriate licence, or any other authorised person, may supply a poison included in Schedule 4 on receipt of a written order, signed by the master of the ship and by the manager, or a person authorised in writing by the manager, of the ship’s agents in the State, certifying that the poison is necessary to complete the equipment of the ship in order to comply with the applicable requirements of subregulation (1).
(3) The person in charge of an aircraft is authorised to be in possession of a poison included in Schedule 4, in a quantity that does not exceed the maximum permitted quantity, as specified by the Department of Transport of the Commonwealth, for the purposes of medical treatment on the aircraft.
(4) The holder of an appropriate licence, or any other authorised person, may supply a poison included in Schedule 4 on receipt of a written order, signed by the manager, or a person authorised in writing by the manager, of the airline company or firm responsible for the operation of the aircraft in the State, certifying that the poison is necessary for the purposes of medical treatment on aircraft.
(1) The master of a ship that is to carry livestock is authorised to procure and be in possession of any poison included in Schedule 4 that is necessary for compliance —
(a) by the exporter with the
Australian Livestock Export Standards — March 2001 (as amended from time to time); or(b) by the master with order 18 of the
Marine Orders Part 43: Cargo and Cargo Handling — Livestock (as amended from time to time) made under theNavigation Act 1912 4 of the Commonwealth.
(2) The holder of an appropriate licence or any other authorised person may supply a poison included in Schedule 4 to the master of a ship on receipt of a written order certifying that the master is authorised under subregulation (1) to procure and be in possession of the poison.
(3) The written order must be signed by the master of the ship himself or herself and by the exporter of the livestock.
(4) The master of a ship must store a poison supplied under subregulation (2) in a secure place on board the ship.
(5) In this regulation —
(1) Subject to subregulation (1aa), until in any particular case such authority is withdrawn —
(a) a medical practitioner;
(aa) a nurse practitioner;
(b) a pharmacist;
(c) a dentist;
(da) an authorised health practitioner;
(d) a veterinary surgeon;
(e) an analyst appointed under the
Health (Miscellaneous Provisions) Act 1911 ;(f) the Director of Nursing of a public hospital or of a private hospital as defined in the
Private Hospitals and Health Services Act 1927 section 2(1);(g) any other person authorised in writing by the CEO,
is authorised to procure, in accordance with subregulation (1a), a poison included in Schedule 4 to the extent that it is required for the purpose of his profession or employment, but such authority does not entitle any person to have in his possession any poison included in Schedule 4 other than in accordance with these regulations or in any quantity greater than is permitted by the CEO.
(1aa) A medical practitioner is not authorised under subregulation (1) to procure a poison included in Schedule 4 and referred to in a regulation listed in the Table, unless the medical practitioner is authorised under that regulation to prescribe the poison.
regulation 38C | regulation 38G |
regulation 38D | regulation 38I |
regulation 38E | regulation 38M |
regulation 38F | regulation 38O |
regulation 38P |
(1AB) Until in any case such authority is withdrawn a podiatrist is authorised to procure and use a poison that is a local anaesthetic included in Schedule 4 —
(a) to the extent required for the purposes of the lawful practice of his or her profession; and
(b) in accordance with these regulations.
(1a) A person authorised under subregulation (1) or (1AB) to procure a poison included in Schedule 4 shall, unless a record is made under regulation 41B in relation to the procurement of the poison, provide a written order to the person from whom he or she is attempting to procure the poison, setting out —
(a) the name, address and signature of the authorised person; and
(b) the date of the order; and
(c) the name and quantity of the poison.
(2) A person who wishes to use any poison included in Schedule 4 being an antibiotic or sulphonamide for the preparation of mixtures for sale pursuant to regulation 39A, and who holds a permit under that regulation to sell such mixtures, is authorised to procure, use and be in possession of such poison included in Schedule 4 for the preparation of such mixtures.
A person who sells or supplies a poison included in Schedule 4 under regulation 36(1), other than to the holder of a prescription under regulation 36(1)(b), may deliver that poison, or cause it to be delivered only —
(a) to the person to whom he or she sold or supplied the poison; or
(b) in accordance with the written directions of a person referred to in paragraph (a).
The CEO may, by notice given to a person referred to in section 23(4) of the Act, revoke the authority conferred on that person by that section in relation to poisons included in Schedule 6, and that revocation may be —
(a) total or subject to strict conditions; and
(b) made in respect of all or any poisons to which the authority relates; and
(c) may be amended or revoked by a further notice.
(1) A person who sells, by retail, any poisons included in Schedule 7 shall, in addition to any conditions and restrictions imposed by notice issued in accordance with these regulations, keep a record of sale by keeping and maintaining a register in accordance with this regulation.
(2) A person recording a sale for the purposes of subregulation (1) shall, before delivering the poison to the purchaser, record in a register kept for that purpose particulars of —
(a) the date of sale; and
(b) the name and address of the purchaser; and
(c) the nature and quantity of the poison sold; and
(d) the address to which the poison is to be delivered, if that address differs from the address recorded under paragraph (b); and
(e) the place of intended use,
and obtain the signature of the purchaser to the entry in the register.
(3) The register shall be kept in one of the following forms —
(a) a book with each recording written in ink; or
(b) in a form of electronic means; or
(c) such other form as the CEO approves in writing.
(4) A person keeping a register for the purposes of this regulation shall —
(a) keep that register for a period of at least 2 years at the licensed premises; and
(b) produce the register for inspection on demand by an authorised officer.
A person shall not sell or supply any preparation for intramammary infusion in animals which contains any antibiotic substance unless it is packed in an applicator device specially designed for intramammary infusion and is suitably coloured with no less than 25 mg per dose of Brilliant Blue FCF so that the visual end point excludes 95% of excreted antibiotic.
A person shall not sell or supply camphor or naphthalene in block, ball, disc or pellet form for domestic use unless the blocks, balls, discs or pellets are enclosed in a device which prevents removal or ingestion of the contents during use.
(1) Every person who holds a licence to procure, manufacture, or supply poisons included in Schedule 3, 4 or 7 by wholesale dealing shall, in relation to the supply of any such poison, keep an accurate record of —
(a) the day on which the poison was supplied; and
(b) the quantity, form and strength of the poison supplied; and
(c) the name and address of the person to whom it was supplied; and
(d) the reference number on the invoice or other document evidencing the supply,
and the record shall be made on the day of supply and shall be kept for not less than 2 years after that day.
(2) A person referred to in subregulation (1) shall send to the CEO particulars in writing of any of the information required to be recorded and kept by that person under subregulation (1) —
(a) within 7 days of being requested to do so where the information has been recorded within 2 months immediately before the request; and
(b) otherwise within 28 days of being requested to do so.
A substance included in Schedule 7 shall not be stored for retail sale in any area or in any manner that allows physical access to that substance by any person other than —
(a) the owner of the business carried on on the premises where it is stored; or
(b) a person employed on the premises where it is stored; or
(c) a person authorised to purchase substances included in Schedule 7 by notice given under section 24 of the Act.
(1) In this regulation —
(a) any education and care service as defined in the
Education and Care Services National Law ( Western Australia ) section 5(1); or(b) any child care service as defined in the
Child Care Services Act 2007 section 4;
(a) a school within the meaning of the
School Education Act 1999 section 4; and(b) a community kindergarten registered under Part 5 of that Act.
(2) Sections 23(1), 31, 32(c) and (d), 34, 46 and 47 of the Act, and regulations 33 and 35A do not apply in relation to a medicine listed in an item in the Table which is supplied or sold —
(a) in the course of activity conducted by a school or child care service; and
(b) as emergency treatment for a condition listed in that item; and
(c) by the method listed in that item.
1. | Adrenaline | Anaphylaxis | Administering by auto-injector |
2. | Salbutamol | Acute asthma | Administering by inhaler |
(3) Section 50 of the Act, and regulations 16, 19, 19AA and 19A do not apply in relation to a medicine listed in an item in the Table if the medicine —
(a) is kept for the purpose of being supplied or sold in the course of activity conducted by a school or child care service as emergency treatment for a condition listed in that item; and
(b) is in a container listed in that item.
1. | Adrenaline | Anaphylaxis | Auto-injector |
2. | Salbutamol | Acute asthma | Inhaler |
In this Part, a reference to prescribing or dispensing a drug of addiction is to be read as including a reference to prescribing or dispensing a preparation containing a drug of addiction.
(1) Until in any particular case such authority is withdrawn —
(a) a medical practitioner; and
(b) a pharmacist employed in dispensing medicines at any public hospital or at a pharmacy for which a pharmacist’s licence is held; and
[(c) deleted] (d) a veterinary surgeon; and
(e) an analyst registered under the
Health (Miscellaneous Provisions) Act 1911 ; and(f) a registered nurse employed in a hospital (so far as the possession or use of such poison included in Schedule 8 is required in connection with its administration to a patient under the instruction of a medical practitioner, nurse practitioner or authorised health practitioner); and
(ga) a registered midwife employed in a hospital (so far as the possession or use of such poison included in Schedule 8 is required in connection with its administration to a patient under the instruction of a medical practitioner, nurse practitioner or authorised health practitioner); and
(g) a person in possession of a permit granted by the CEO under these regulations,
is, subject to these regulations, hereby authorised to procure and be in possession of any poison included in Schedule 8 for the purpose of his or her profession or employment.
(2A) An authorised health practitioner is authorised to procure a poison included in Schedule 8 for the purpose of his or her profession or employment.
(2) A person in respect of whom a prescription for a poison included in Schedule 8 is issued is hereby authorised to procure and have possession of the poison included in Schedule 8 to the extent specified in the prescription.
(3) The authority under this regulation to procure and be in the possession of any poison included in Schedule 8 does not entitle the holder to procure or have in his possession any poison included in Schedule 8 in any quantity greater than is permitted by the CEO.
(4) Until in any particular case such authority is withdrawn a dentist is, subject to these regulations and for the purpose of his profession, hereby authorised to procure and be in possession of the following poisons included in Schedule 8 in quantities not greater than those set out hereunder —
PETHIDINE in a form prepared for injection with a total pethidine content of 600 mg |
PAPAVERETUM, in tablet form, with a total papaveretum content of 240 mg |
CODEINE PHOSPHATE, in tablet form, with a total codeine phosphate content of 900 mg |
METHADONE, in tablet form, with a total methadone content of 240 mg |
MORPHINE, in a form prepared for injection, with a total morphine content of 180 mg |
OXYCODONE, in tablet form, with a total oxycodone content of 120 mg |
PENTAZOCINE, in a form prepared for injection, with a total pentazocine content of 360 mg. |
(1) Until in any particular case such authority is withdrawn, every pharmacist holding a pharmacist’s licence to sell poisons under these regulations is hereby authorised, subject to the conditions, limitations and restrictions imposed by the CEO, to procure and to manufacture at his registered premises in the ordinary course of his retail business any preparation, admixture, or extract of any poison included in Schedule 8, and to carry on at his registered premises the business of dispensing or compounding any poison included in Schedule 8, and also of retailing and supplying a poison included in Schedule 8, but only to persons licensed or authorised under these regulations to be in possession of or to procure the poison included in Schedule 8.
(2) The authority under this regulation does not in any way entitle the holder to procure, manufacture, sell, distribute, supply, or have in his possession any poison included in Schedule 8 in any quantity greater than is permitted by the CEO.
The CEO may, by notice given to a person referred to in section 23(2) of the Act, revoke the authority conferred on that person by that section in relation to poisons included in Schedule 8 or specified drugs or both, and that revocation may be —
(a) total or subject to strict conditions; and
(b) made in respect of all or any specified drugs or poisons to which the authority relates; and
(c) may be amended or revoked by a further notice.
For the purposes of section 41(1) of the Act —
(a) analytical chemical analysis; and
(b) anaesthesia of exotic animals; and
(c) training animals for the detection of substances included in Schedule 9 to the Act,
are purposes for which a specified person may be authorised under that subsection to manufacture, prepare, possess or use a specified substance included in Schedule 9 to the Act.
A substance included in Schedule 8 shall not be advertised except in a publication that is normally sold or intended for sale or circulation only among —
(a) persons of the kind referred to in section 23(2) of the Act; or
(b) persons who are holders of a licence granted under section 24(1)(a), (b) or (c) of the Act.
(1) In this regulation —
(2) An authorised person must maintain a register of the drugs of addiction manufactured, procured, used, supplied or kept by, or on behalf of, the person.
(3) An authorised person is to record, or cause to be recorded, in the register, in relation to each transaction involving a drug of addiction —
(a) the name, quantity and form of the drug; and
(b) the date of the transaction; and
(c) the name and address of each other person or firm involved in the transaction; and
(d) the name of the person who issued the prescription or order; and
(e) the amount of the drug remaining on hand after the transaction; and
(f) if the authorised person is a pharmacist, the identifying number of the prescription; and
(g) if the authorised person is a manufacturer or distributor, an identifying number of the order or other authority on which the drug is supplied,
and, if the register is maintained on paper, is to sign that entry in the register.
(3a) An authorised person is to record, or cause to be recorded, in the Register the result of each inventory made by the authorised person under regulation 45 on the day on which the inventory is made.
(4) The register must be maintained in such a way that at any time the amount of each drug of addiction manufactured, procured, used, supplied or kept by the authorised person is clearly apparent.
(5) An authorised person must —
(a) maintain a separate register for each location at which the person manufactures, procures, uses, supplies or keeps drugs of addiction; and
(b) keep the register at that location.
(1) Subject to subregulations (2) and (3) a person authorised to manufacture, distribute, procure, sell or possess a drug of addiction (other than a person who possesses a poison included in Schedule 8 under a prescription issued by a medical practitioner, nurse practitioner, dentist or veterinary surgeon) shall not wilfully destroy that drug of addiction.
(2) Subject to regulation 31 a drug of addiction may be destroyed by —
(a) or under the personal supervision of a person declared to be an authorised officer for the purposes of this regulation by the Minister under section 52A of the Act; or
(b) a police officer acting under the
Misuse of Drugs Act 1981 .
(3) Subject to regulation 31 a person referred to in subregulation (1), other than a person to whom subregulation (2) applies, who seeks to destroy a poison included in Schedule 8 shall carry out that destruction under the supervision of a witness selected, in accordance with subregulation (7), from any of the following categories —
(a) pharmacists authorised to possess and supply poisons included in Schedule 8; and
(b) medical practitioners or nurse practitioners authorised to supply poisons included in Schedule 8; and
(c) directors of nursing.
(4) A person who destroys poisons included in Schedule 8 must maintain a register of the poisons destroyed and record in it, at the time of each destruction —
(a) the date of destruction; and
(b) the name, strength and quantity of the poison destroyed; and
(c) the reason for the destruction; and
(d) the name of the witness to the destruction,
and, if the register is maintained on paper, is to sign, and cause the witness to sign, that entry in the register.
(5) A pharmacist required to provide a monthly return under regulation 52C shall, as part of the return, provide details of the entries recorded in the register, maintained in accordance with subregulation (4), for the relevant period.
(6) Where the monthly return referred to in subregulation (5) is made —
(a) on the original of the approved duplicate form, the details shall be entered by the person who destroyed the poison included in Schedule 8 and that person and the person who supervised the destruction shall each sign the entry;
(b) on the original of the completed printout of the approved computerised recording system, the details shall be accompanied by the name of the person who destroyed the poison included in Schedule 8 and that of the witness who supervised the destruction of the poison.
(7) For the purposes of subregulation (3), a pharmacist, authorised to possess and supply poisons included in Schedule 8 or Schedule 9, who wishes to destroy poisons included in Schedule 8 or Schedule 9 may have another pharmacist authorised to possess and supply poisons included in Schedule 8 or Schedule 9 as a witness to that destruction, but otherwise a witness shall not be a member of the same category as that of the person who seeks to destroy the poisons included in Schedule 8.
(1) A register kept for the purposes of regulation 44(2) or 44A(4) may be maintained on paper, electronically or in another approved manner.
(1a) If a register is maintained on paper, all entries required to be made in the register are to be made in ink.
(2) If a register is maintained other than on paper the information in the register must be recorded or stored in such a way that it —
(a) will remain in the form in which it was originally recorded or stored; and
(b) is capable of being reproduced in written form on paper.
(3) The register must be maintained in a form and manner approved by the CEO.
(4) An authorised person must make all the person’s registers available for inspection on request by persons authorised under the Act to inspect registers.
(5) Subject to subregulation (6) a person must not alter, obliterate or delete an entry in a register.
(6) An authorised person may correct an error in a register —
(a) if the register is maintained on paper, by making a marginal or foot note and initialling and dating the note; or
(b) otherwise, in a manner approved by the CEO.
(1) In this regulation —
(2) An authorised person must maintain the register in such a way that entries in the register cannot be deleted.
(3) An authorised person must maintain the register in such a way that —
(a) entries in the register cannot be made by any person who does not use a system identifier issued by the authorised person; and
(b) a system identifier cannot be used other than in combination with an access code for the person to whom the system identifier was issued; and
(c) whenever a person makes an entry in the register the system identifier of that person is automatically recorded in the register; and
(d) the record of the system identifier cannot be changed.
(4) The authorised person must keep a record of the system identifiers issued for the purposes of this regulation and the persons to whom they have been issued and must ensure that other persons do not have access to that record.
(5) In any legal proceedings under this Act or the
Misuse of Drugs Act 1981 , if it is proved that the system identifier issued to a person has been recorded in the register in respect of an entry, then in the absence of evidence to the contrary that person is taken to have made the entry.
(1) An inventory of drugs of addiction held in stock shall be made —
(a) at intervals of not more than one month by every person required to keep a Register of Drugs of Addiction; and
(b) by a person who is about to relinquish control of drugs of addiction; and
(c) forthwith on assuming control by any person who assumes control of drugs of addiction,
and the result of that inventory is to be recorded in the Register in accordance with regulation 44(3a).
(2) If such inventory of drugs of addiction in stock does not agree with the balance recorded in the Register, the person required to keep the Register shall immediately notify the CEO in writing of the discrepancy.
(1) All records, registers, prescription books, invoices and other documents relating to drugs of addiction, and transactions in regard thereto shall be kept by the person licensed or authorised to have drugs of addiction in his possession for not less than 7 years from the latest date on which such record, register, prescription book, invoice or other document was made or acted upon.
(2) The records, registers, prescription books, invoices or other documents and stocks of drugs of addiction on hand shall be made available for inspection on demand by an authorised officer and shall be accounted for, during the inspection, by the person licensed or authorised to have drugs of addiction in his possession.
(3) In the event of a register being lost or destroyed the person to whom such register belongs shall upon becoming aware of the loss or destruction make and forward to the CEO a statutory declaration concerning that loss or destruction and shall immediately take stock of all drugs of addiction in his possession and enter particulars of those stocks in a new register in accordance with the requirements of these regulations.
(4) A person authorised or licensed to procure and be in possession of a drug of addiction, on ceasing to be so authorised or licensed shall, if requested by the CEO, surrender any records, registers, prescription books, invoices or other documents and stocks of drugs of addiction that are in his possession to the CEO.
(5) A person required by these regulations to make and keep records, registers, returns, prescription books, invoices and other documents relating to drugs of addiction shall not make any entry therein which is false or untrue in any particular.
(6) The duplicate copy of the form or printout of the computerised recording system approved by the CEO for the purposes of regulation 52B is a record to be retained for the purposes of this regulation and, in the case of a transaction referred to in regulation 52(3)(h), it shall be kept at the place at which the poison was dispensed for at least one year from the date of the transaction.
(1) Every person who is licensed under regulation 3 shall complete and forward to the CEO, every 7 days a form approved by the CEO for that purpose, reporting all transactions in poisons included in Schedule 8 made by him during that week.
(2) The form referred to in subregulation (1) may be required by the CEO to be in a code approved by him from time to time and shall describe the composition, form, strength, size and quality of each poison included in Schedule 8 and identify the person from whom, or to whom a poison included in Schedule 8 has been obtained or supplied.
(1) The master of a certificated commercial vessel is authorised to procure and be in possession of any poison included in Schedule 8 that is necessary to complete the equipment of the vessel in order to comply with the requirements of the
Western Australian Marine Act 1982 .(2) The holder of an appropriate licence, or any other authorised person, may supply a poison included in Schedule 8 on receipt of a written order, signed by the master of the certificated commercial vessel, certifying that the poison is necessary to complete the equipment of the vessel in order to comply with the applicable requirements of subregulation (1).
(3) The written order referred to in subregulation (2) must contain all of the following information —
(a) the date of the order;
(b) the name of the certificated commercial vessel;
(c) the machinery and hull number;
(d) the name, address and signature of the master of the vessel;
(e) the quantity, form and strength of the poison ordered.
(4) The master of the certificated commercial vessel must ensure that —
(a) so far as is practicable, the poisons supplied under subregulation (2) are stored in a manner that prevents their theft, loss or unauthorised use; and
(b) a record is kept of all the poisons stored aboard the vessel.
(5) When a medical practitioner authorises the administration of one of the poisons to a person on board the certificated commercial vessel, the master of the vessel must ensure that a record is kept of all of the following information —
(a) the date on which the poison was administered;
(b) the poison being administered, the strength of the poison and the quantity that has been administered;
(c) the name of the person to whom the poison has been administered;
(d) the name and address of the medical practitioner who authorised the administration of the poison.
(1) The owner of a racing yacht is authorised to procure and be in possession of any poison included in Schedule 8 that is necessary to complete the equipment of the yacht in order to comply with the requirements of the rules known as the “Racing Rules of Sailing” made by Yachting Australia Incorporated.
(2) The holder of an appropriate licence, or any other authorised person, may supply a poison included in Schedule 8 on receipt of a written order, signed by the owner of the racing yacht, certifying that the poison is necessary to complete the equipment of the yacht in order to comply with the applicable requirements of subregulation (1).
(3) The written order referred to in subregulation (2) must contain all of the following information —
(a) the date of the order;
(b) the name of the racing yacht;
(c) the registration number of the racing yacht;
(d) the name of the yacht club organising the race;
(e) the name, address and signature of the owner of the yacht;
(f) the quantity, form and strength of the poison ordered.
(4) The owner of the racing yacht must ensure that —
(a) so far as is practicable, the poisons supplied under subregulation (2) are stored in a manner that prevents their theft, loss or unauthorised use; and
(b) a record is kept of all the poisons stored aboard the yacht.
(5) When a medical practitioner authorises the administration of one of the poisons to a person on board the racing yacht, the skipper of the yacht must ensure that a record is kept of all of the following information —
(a) the date on which the poison was administered;
(b) the poison being administered, the strength of the poison and the quantity that has been administered;
(c) the name of the person to whom the poison has been administered;
(d) the name and address of the medical practitioner who authorised the administration of the poison.
(1) The master of a ship other than a certificated commercial vessel or a racing yacht is authorised to procure and be in possession of any poison included in Schedule 8 that is necessary to complete the equipment of the ship in order to comply with the requirements of —
(a) if the ship is registered in
Australia —(i) section 125 of the
Navigation Act 1912 4 of the Commonwealth; or(ii) the navigation authority of any State of Australia;
or
(b) if the ship is not registered in
Australia —(i) a law applying to ships in the country in which the ship is registered; or
(ii) the “
International Medical Guide for Ships ” (2nd. Edition), as published by the World Health Organization.
(2) The holder of an appropriate licence, or any other authorised person, may supply a poison included in Schedule 8 on receipt of a written order, signed by the master of the ship and by the manager, or a person authorised in writing by the manager, of the ship’s agents in the State, certifying that the poison included in Schedule 8 is necessary to complete the equipment of the ship in order to comply with the applicable requirements of subregulation (1).
(3) The person in charge of an aircraft is authorised to be in possession of a poison included in Schedule 8, in a quantity that does not exceed the maximum permitted quantity specified by the Department of Transport of the Commonwealth, for the purposes of medical treatment on the aircraft.
(4) The holder of an appropriate licence, or any other authorised person, may supply a poison included in Schedule 8 on receipt of a written order, signed by the manager, or a person authorised in writing by the manager, of the airline company or firm responsible for the operation of the aircraft in the State, certifying that the poison included in Schedule 8 is necessary for the purposes of medical treatment on aircraft.
(5) Any person who supplies a poison included in Schedule 8 under this regulation shall, within 24 hours of so doing, report the details to the CEO or the officer in charge of the nearest police station.
(1) In a hospital, the ordering, issuing, storing and keeping of records as required by these regulations of all poisons included in Schedule 8 is the responsibility of —
(a) if the hospital has a pharmacy department, the pharmacist in charge of the pharmacy department; or
(b) otherwise, the director of nursing of the hospital or another person authorised in writing by the CEO.
(2) A poison included in Schedule 8 must not be administered to a patient in a hospital unless —
(a) it is administered by a medical practitioner, nurse practitioner, dentist, endorsed midwife or endorsed podiatrist; or
(b) the administration of the poison is authorised in writing on the medication chart of the patient by a medical practitioner, nurse practitioner, dentist or endorsed podiatrist; or
(c) the administration of the poison to the patient is verbally authorised by a medical practitioner, nurse practitioner, dentist or endorsed podiatrist.
(3) If a medical practitioner, nurse practitioner, dentist or endorsed podiatrist verbally authorises the administration of a poison to a patient in a hospital the medical practitioner, nurse practitioner, dentist or endorsed podiatrist must, within 24 hours of the verbal authorisation, note the authorisation on the medication chart of the patient.
(1) A prescription for the supply of a drug of addiction shall comply with the following conditions —
(a) it shall include —
(i) the name and address of the prescriber; and
(ii) the name, address and date of birth of the patient or, in the case of a prescription for veterinary use, the name and address of the person having the care of the animal for which the prescription is intended; and
(iii) the description and quantity of the drug to be dispensed; and
(iv) precise directions for the use of the drug, including the dose to be taken or administered and the frequency with which the dose is to be taken or administered; and
(v) the date when it was written; and
(vi) if the drug is to be dispensed more than once under the prescription — the maximum number of times it may be repeated and the intervals at which it may be dispensed;
(b) it shall not prescribe more than one drug of addiction, or any other substance, but may prescribe the same drug in more than one form;
(c) if issued by a dentist — it shall include the words “for dental treatment only” and if issued by a veterinary surgeon — it shall include the words “for animal treatment only”;
(d) if it prescribes an unusual dose it shall indicate that such a dose was intended by —
(i) in the case of a prescription that is not issued electronically — that part of the prescription being underlined and initialled by the prescriber in the margin; and
(ii) in the case of a prescription that is issued electronically — the means provided by the approved electronic prescribing system;
(e) it shall be issued in a manner provided for in subregulation (1A) or (1B).
(1A) A prescription that is issued electronically shall be issued via an approved electronic prescribing system.
(1B) A prescription that is not issued electronically shall be either —
(a) written in ink in the prescriber’s own handwriting; or
(b) processed on an approved computer program and have the information referred to in subregulation (1)(a)(iii), (iv) and (vi) written in ink in the prescriber’s own handwriting.
The prescription shall be signed by the prescriber in his or her own handwriting.
(1C) In subregulation (1B) —
(a) complies with the criteria specified in Appendix L; or
(b) is recommended by the Poisons Advisory Committee and approved in writing by the CEO.
(2) With the written approval of the CEO a person authorised to prescribe drugs of addiction may issue a typewritten prescription where the CEO is satisfied that by reason of physical infirmity the prescriber is unable to write legibly in his or her own handwriting but in that case the prescriber shall sign the prescription with his or her usual signature.
(1) In this regulation —
(2) An NIMC for a patient who is discharged from a public hospital is to be taken to be a prescription for a Schedule 8 poison that complies with regulation 51 for the purposes of dispensing the Schedule 8 poison at the public hospital on the discharge of the patient if —
(a) all the details in respect of the patient required by the NIMC have been completed; and
(b) a medical practitioner, nurse practitioner or endorsed podiatrist has completed, in ink in his or her own hand writing, all the details in respect of the Schedule 8 poison required by the NIMC; and
(c) a medical practitioner, nurse practitioner or endorsed podiatrist has written, in ink, an authorisation on the NIMC for the Schedule 8 poison to be dispensed for discharge, and dated and signed the authorisation.
(1) In this Subdivision —
(a) is under a state of periodic or chronic intoxication produced by consumption of a drug of addiction or any substitute; or
(b) is under a desire or craving to take a drug of addiction or any substitute until he or she has so satisfied that desire or craving; or
(c) is under a psychic or physical dependence to take a drug of addiction or any substitute; or
(d) is listed in the register of information kept under the
Drugs of Addiction Notification Regulations 1980 ;
(a) the “Clinical policies and procedures for the use of methadone and buprenorphine in the treatment of opioid dependence” published from time to time by the department of the Public Service principally assisting in the administration of the
Alcohol and Other Drugs Act 1974 ; or(b) until that department first publishes the policies and procedures referred to in paragraph (a) — the “Clinical policies and procedures for the use of methadone and buprenorphine in the treatment of opioid dependence” last published by the Drug and Alcohol Office Western Australia before the day on which the
Alcohol and Drug Authority Amendment Act 2015 section 8 comes into operation;
(2) In this Subdivision, a reference to prescribing a drug of addiction or a pharmacotherapy is a reference to writing, issuing or authorising a prescription or document prescribing the use, sale or supply of the drug of addiction or pharmacotherapy.
A drug addict must, when seeking to obtain from a medical practitioner, nurse practitioner, authorised health practitioner or dentist —
(a) a drug of addiction; or
(b) a prescription or document prescribing the use, sale or supply of a drug of addiction,
disclose to the medical practitioner, nurse practitioner, authorised health practitioner or dentist the fact that he or she is a drug addict.
(1) A person must not prescribe or supply a drug of addiction for the treatment of a person who is a drug addict unless the person is authorised to do so under this Subdivision.
(2) A person who is authorised under this Subdivision to prescribe or supply a drug of addiction for the treatment of a drug addict must do so in accordance with the Policies Manual, except to the extent to which an authorisation, designation or appointment of the person under this Subdivision is inconsistent with the manual.
(1) A medical practitioner, nurse practitioner, authorised health practitioner or dentist may administer a drug of addiction for the treatment of a person who is a drug addict.
(2) A medical practitioner, nurse practitioner or dentist may prescribe or supply a drug of addiction for the treatment of a person who is a drug addict if the medical practitioner, nurse practitioner or dentist —
(a) has been authorised by the CEO under this subregulation to do so for that drug addict; and
(b) does so in accordance with the authorisation.
(3) Subregulations (1) and (2) do not authorise a medical practitioner, nurse practitioner or dentist to prescribe or supply a pharmacotherapy for the treatment of the drug addiction of a person who is a drug addict.
(1) The CEO may designate a medical practitioner or a nurse practitioner as an authorised prescriber for the purposes of this Subdivision.
(2) The CEO may designate an authorised prescriber as a specialist prescriber for the purposes of this Subdivision.
(1) The CEO may appoint an authorised prescriber to be the authorised prescriber for a person who is a drug addict.
(2) The appointment as the authorised prescriber for a person is for the period specified in the instrument of appointment.
(3) The instrument of appointment must be given to the authorised prescriber.
(1) A specialist prescriber who is the authorised prescriber for a person who is a drug addict may appoint a medical practitioner or nurse practitioner (who need not be an authorised prescriber) to be a co‑prescriber for the person.
(2) The appointment as a co‑prescriber —
(a) is for the period specified in the instrument of appointment, which cannot be more than 12 months; and
(b) ceases on the earlier of —
(i) the end of the period of appointment; or
(ii) the specialist prescriber ceasing to be the authorised prescriber for the person.
(3) The instrument of appointment must be given to the co‑prescriber and a copy must be given to the CEO.
A designation, authorisation or appointment of a person under this Subdivision —
(a) must be in writing; and
(b) may be subject to conditions; and
(c) may be amended, suspended or revoked at any time.
(1) A medical practitioner or nurse practitioner may prescribe a pharmacotherapy for the treatment of the drug addiction of a person who is a drug addict if the medical practitioner or nurse practitioner —
(a) is an authorised prescriber; and
(b) is appointed as the authorised prescriber for the person; and
(c) does so in accordance with that appointment.
(2) A medical practitioner or nurse practitioner may prescribe a pharmacotherapy for the treatment of the drug addiction of a person who is a drug addict if the medical practitioner or nurse practitioner —
(a) is an authorised prescriber; and
(b) is a member of the same medical practice as the authorised prescriber appointed for the person; and
(c) has access to the medical records of the practice relating to the person; and
(d) does so in accordance with the appointment of the authorised prescriber for the person.
(3) A medical practitioner or nurse practitioner may prescribe a pharmacotherapy for the treatment of the drug addiction of a person who is a drug addict if the medical practitioner or nurse practitioner —
(a) is a co‑prescriber for the person; and
(b) does so in accordance with —
(i) his or her appointment as a co‑prescriber; and
(ii) the appointment of the authorised prescriber for the person.
(4) A medical practitioner or nurse practitioner may prescribe a pharmacotherapy for the treatment of the drug addiction of a person who is a drug addict if the medical practitioner or nurse practitioner —
(a) is a member of the same medical practice as a co‑prescriber for the person; and
(b) is satisfied that the co‑prescriber for the person is absent from the medical practice or is otherwise unable to prescribe a pharmacotherapy for the treatment of the drug addiction of the person; and
(c) has access to the medical records of the practice relating to the person; and
(d) does so in accordance with —
(i) the appointment of the co‑prescriber for the person; and
(ii) the appointment of the authorised prescriber for the person.
(5) A prescription for the supply of a pharmacotherapy —
(a) under subregulation (3) — may not cover a period of more than 3 months; or
(b) under subregulation (4) — may not cover a period of more than one month.
(1) A medical practitioner or nurse practitioner may prescribe a pharmacotherapy for the treatment of the drug addiction of a person who is a patient in a hospital and who is a drug addict if —
(a) an authorised prescriber is appointed for the person; and
(b) the medical practitioner or nurse practitioner is satisfied that it is safe to prescribe a pharmacotherapy for the person; and
(c) the medical practitioner or nurse practitioner does so in accordance with the appointment of the authorised prescriber for the person.
(2) Subregulation (1) does not authorise the medical practitioner or nurse practitioner to prescribe a pharmacotherapy unless it will be administered to the person while the person is a patient in the hospital.
(3) For the purposes of this regulation, a person is a patient in a hospital while the person is admitted as a patient to the hospital.
(4) A prescription for the supply of a pharmacotherapy under this regulation may not cover a period of more than one month.
(1) A medical practitioner or nurse practitioner may prescribe a pharmacotherapy for the treatment of the drug addiction of a person who is in custody and who is a drug addict if —
(a) an authorised prescriber is appointed for the person; and
(b) the medical practitioner or nurse practitioner is satisfied that it is safe to prescribe a pharmacotherapy for the person; and
(c) the medical practitioner or nurse practitioner does so in accordance with the appointment of the authorised prescriber for the person.
(2) Subregulation (1) does not authorise the medical practitioner or nurse practitioner to prescribe a pharmacotherapy unless it will be administered to the person while the person is in custody.
(3) A prescription for the supply of a pharmacotherapy under this regulation may not cover a period of more than one month.
(1) A specialist prescriber may prescribe a pharmacotherapy for the treatment of the drug addiction of a person who is a drug addict if —
(a) an authorised prescriber is appointed for the person; and
(b) the specialist prescriber —
(i) is satisfied that the person is unable to obtain a prescription for a pharmacotherapy under regulation 51D, 51DA or 51DB; and
(ii) is satisfied that it is safe to prescribe a pharmacotherapy for the person; and
(iii) does so in accordance with the appointment (whether or not it has ceased) of the authorised prescriber for the person.
(2) The specialist prescriber must, as soon as is practicable, notify the CEO, and (where relevant) the authorised prescriber for the person, of having prescribed a pharmacotherapy for a person under this regulation.
(3) A prescription for the supply of a pharmacotherapy under this regulation may not cover a period of more than one month.
A pharmacist or an assistant under the direct personal supervision of a pharmacist may dispense a drug of addiction, other than a pharmacotherapy, to a person who is a drug addict.
(1) The CEO may authorise the dispensing of pharmacotherapies at a pharmacy.
(2) A pharmacist or an assistant under the direct personal supervision of a pharmacist may dispense a pharmacotherapy to a person who is a drug addict if the pharmacist or assistant does so in accordance with an authorisation governing the dispensing of pharmacotherapies at the pharmacy.
(3) Pharmacotherapies cannot be dispensed at a pharmacy unless there is an authorisation applying to the dispensing of pharmacotherapies at the pharmacy.
(1) A medical practitioner or nurse practitioner shall not write, issue or authorise a prescription or document prescribing the use, sale or supply of a poison included in Schedule 8, or supply a poison included in Schedule 8, for the treatment of a person, other than a drug addict, for a period in excess of 60 days, or for periods that in the aggregate over the preceding 12 months exceed 60 days, or for a course of treatment exceeding 60 days, unless he has first obtained written authorisation to do so from the CEO.
(2) Where a medical practitioner or nurse practitioner has written, issued or authorised a prescription or document prescribing the use, sale or supply of a poison included in Schedule 8, for the treatment of a person other than a drug addict, or supplied a poison included in Schedule 8 for the treatment of a person, other than a drug addict, for a period of 60 days, or for periods that in the aggregate over the preceding 12 months exceed 60 days, or for a course of treatment exceeding 60 days, the medical practitioner or nurse practitioner shall not thereafter write, issue or authorise a prescription or document prescribing the use, sale or supply of a poison included in Schedule 8 in relation to that person or supply a poison included in Schedule 8 in relation to that person unless —
(a) the medical practitioner or nurse practitioner has first obtained written authorisation under this regulation to do so from the CEO; or
(b) the CEO has issued an authorisation under this regulation to do so in relation to that person and the authorisation is current.
(3) Notwithstanding any authorisation referred to in subregulation (1) or (2) a medical practitioner or nurse practitioner shall not write, issue or authorise a prescription or document prescribing the use, sale or supply of methadone or buprenorphine for the treatment of a person or supply methadone or buprenorphine for the treatment of a person except for a person suffering from intractable pain arising from a condition of health other than addiction to drugs.
(4) In any authorisation issued for the purposes of subregulation (1) or (2) given with respect to a particular person the CEO may specify that any one or more of the conditions and restrictions set out below apply, namely —
(a) that the prescription be issued by or the treatment be administered by a specified medical practitioner or nurse practitioner;
(b) that only a specified poison included in Schedule 8 be prescribed or used for treatment;
(c) that the type of the poison included in Schedule 8 specified be of the type specified;
(d) that the amount to be prescribed or used for treatment shall not exceed the amount specified;
(e) that the amount to be prescribed or used on any one day shall not exceed the amount specified;
(f) that the concentration to be prescribed shall not exceed the concentration specified;
(g) that the intervals between the issue of prescriptions or the administration of the poison included in Schedule 8 shall be such as are specified;
(h) that the prescription be supplied at the pharmacy specified;
(i) that the amount dispensed on a single prescription not exceed such amount as is specified;
(j) that the amount that may be supplied on any one day shall not exceed such amount as is specified.
(5) An authorisation issued for the purposes of subregulation (1) or (2) is valid for such period as is specified unless revoked by the CEO before the expiration of that period.
(6) A medical practitioner or nurse practitioner shall not write, issue or authorise a prescription or document prescribing the use, sale or supply of a poison included in Schedule 8 or supply a poison included in Schedule 8 otherwise than in accordance with such conditions and restrictions as are specified.
(7) A pharmacist shall not sell or supply a poison included in Schedule 8 otherwise than in accordance with such conditions and restrictions as are specified pursuant to this regulation.
(8) An authorisation issued prior to 1 October 1980 is valid until revoked by the CEO or until it expires whichever first occurs.
In this Subdivision —
(a) a nominated co‑prescriber for the patient; or
(b) a medical practitioner or nurse practitioner who is a co‑prescriber for the patient under regulation 51FH(5);
(1) A person must not supply or prescribe a stimulant unless —
(a) the person —
(i) is a medical practitioner or a nurse practitioner; and
(ii) one of subregulations (2) to (5) applies;
or
(b) the person —
(i) is a pharmacist, or an assistant under the direct personal supervision of a pharmacist; and
(ii) dispenses the stimulant in accordance with regulation 52.
(2) This subregulation applies if the person, being a medical practitioner —
(a) is authorised under regulation 51FG as an SPN practitioner; and
(b) supplies or prescribes the stimulant in accordance with that authorisation.
(3) This subregulation applies if the medical practitioner or nurse practitioner —
(a) is a co‑prescriber for the patient; and
(b) supplies or prescribes the stimulant in the manner specified in the most recent notification about the patient given to the CEO under regulation 51FE.
(4) This subregulation applies if the medical practitioner or nurse practitioner —
(a) is authorised under regulation 51FG(3) to supply or prescribe the stimulant to or for the patient; and
(b) supplies or prescribes the stimulant in accordance with that authorisation.
(5) This subregulation applies if —
(a) the patient has a current prescriber or current clinic; and
(b) the patient —
(i) is an in‑patient in a hospital within the meaning given in the
Health Services Act 2016 section 8(4); or(ii) is in custody in a prison as defined in the
Prisons Act 1981 section 3(1); or(iii) is in custody in a detention centre as defined in the
Young Offenders Act 1994 section 3,
and has been in the hospital, prison or detention centre for not more than 3 months; and
(c) the medical practitioner’s or nurse practitioner’s practice is, or includes, treating persons at the hospital, prison or detention centre; and
(d) the current prescriber or a current clinic prescriber has agreed with the medical practitioner or nurse practitioner that the patient should continue to be supplied or prescribed the stimulant; and
(e) the medical practitioner or nurse practitioner supplies or prescribes the stimulant in the manner specified in the most recent notification about the patient given to the CEO under regulation 51FE.
(6) Subregulation (5) ceases to apply in relation to a patient at the expiry of 3 months after the day on which the medical practitioner or nurse practitioner first supplies or prescribed stimulants to or for the patient.
(1) A medical practitioner or nurse practitioner must not supply or prescribe a stimulant unless he or she does so —
(a) in accordance with the Stimulant Prescribing Code; or
(b) in accordance with an authorisation granted under subregulation (2) or (4).
(2) The CEO may authorise an SPN practitioner to supply or prescribe a stimulant to or for a particular patient other than in accordance with the Stimulant Prescribing Code.
(3) An application for an authorisation under subregulation (2) must be made to the CEO in a form approved by the CEO.
(4) The CEO may, when authorising a medical practitioner or nurse practitioner under regulation 51FG(3), also authorise that practitioner to supply or prescribe the stimulant other than in accordance with the Stimulant Prescribing Code.
(5) The CEO must not grant an authorisation under subregulation (2) or (4) unless satisfied that there are good medical grounds for doing so.
(6) Subject to subregulation (5), the CEO may grant, or refuse to grant, an authorisation under subregulation (2) or (4) as the CEO thinks fit.
(7) The CEO may grant an authorisation under subregulation (2) or (4) on any terms and conditions the CEO thinks fit.
(8) An authorisation granted under subregulation (2) extends to any co‑prescriber for the patient who is named in the authorisation.
(9) The CEO may vary or revoke an authorisation granted under subregulation (2) or (4) at any time by giving written notice to the medical practitioner or nurse practitioner.
(10) An authorisation granted under subregulation (2) ceases if the SPN practitioner ceases to be the patient’s current prescriber.
(1) If a stimulant is being supplied or prescribed to or for a patient the CEO may, by giving notice in accordance with subregulation (2), order that the supply or prescription be terminated or varied.
(2) Notice of an order must be given in writing —
(a) if the patient has a current prescriber — to that prescriber; or
(b) if the patient has a current clinic — to the manager of that clinic; or
(c) if the stimulant is being prescribed by a medical practitioner or nurse practitioner authorised under regulation 51FG(3) — to that practitioner.
(3) A person who is given a notice under subregulation (2) must give a copy of it —
(a) to any nominated co‑prescriber for the patient; and
(b) if the patient is being treated by a medical practitioner or nurse practitioner as permitted under regulation 51FB(5) — to that practitioner.
(4) A medical practitioner or nurse practitioner must not supply or prescribe a stimulant in contravention of an order made under subregulation (1).
(1) If an SPN practitioner supplies or prescribes a stimulant to or for a patient the practitioner must give a notification about the patient to the CEO unless the practitioner is a current prescriber or current clinic prescriber for the patient.
(2) A current prescriber or current clinic prescriber for a patient must give an updated notification about the patient to the CEO as soon as practicable after any of the following occurs —
(a) there is a change in the dose, type or form of stimulant being supplied or prescribed to or for the patient;
(b) there is a change in the patient’s name or residential address;
(c) in the case of a current prescriber — the prescriber ceases supplying or prescribing the stimulant to or for the patient;
(d) in the case of a current clinic prescriber — all current clinic prescribers at the clinic cease supplying or prescribing the stimulant to or for the patient.
(3) A current clinic prescriber is not required to give a notification under subregulation (2) as a result of the occurrence of a particular event if another prescriber at the clinic has given a notification as a result of that occurrence.
(4) A person who gives a notification under subregulation (1) or (2) must give a copy of it —
(a) to any nominated co‑prescriber for the patient; and
(b) if the patient is being treated by a medical practitioner or nurse practitioner as permitted under regulation 51FB(5) — to that practitioner.
(5) A medical practitioner or nurse practitioner authorised under regulation 51FG(5) who supplies or prescribes a stimulant to or for a patient must —
(a) give a notification about the patient to the CEO; and
(b) give a copy of the notification to the patient’s current prescriber or the manager of the patient’s current clinic.
(6) A notification for the purposes of this regulation must be in a form approved by the CEO.
(1) When the CEO receives a notification about a patient under regulation 51FE(1) —
(a) unless paragraph (b) applies — the practitioner giving the notification becomes the patient’s current prescriber; or
(b) if —
(i) the practitioner giving the notification practises at an approved clinic; and
(ii) the supply or prescription of the stimulant is in accordance with the Stimulant Prescribing Code,
the clinic becomes the patient’s current clinic.
(2) If, when the CEO receives a notification under regulation 51FE(1), the patient already has a current prescriber or current clinic, the CEO is to give written notice of the new notification to the current prescriber or the manager of the current clinic.
(3) A patient’s current prescriber ceases to be his or her current prescriber if —
(a) the prescriber is given a notice under subregulation (2); or
(b) the practitioner gives an updated notification under regulation 51FE(2)(c); or
(c) the current prescriber is given a notice under regulation 51FD ordering that the supply or prescription of the stimulant to or for the patient be terminated.
(4) A patient’s current clinic ceases to be his or her current clinic if —
(a) the manager of the clinic is given a notice under subregulation (2); or
(b) a current clinic prescriber gives an updated notification under regulation 51FE(2)(d); or
(c) the manager of the clinic is given a notice under regulation 51FD ordering that the supply or prescription of the stimulant to or for the patient be terminated.
(5) A person who is given a notice under subregulation (2) must give a copy of it —
(a) to any nominated co‑prescriber for the patient; and
(b) if the patient is being treated by a medical practitioner or nurse practitioner as permitted under regulation 51FB(5) — to that practitioner.
(1) The CEO may authorise a medical practitioner to supply and prescribe stimulants to or for the practitioner’s patients.
(2) Each medical practitioner authorised under subregulation (1) is to be assigned a unique stimulant prescriber number.
(3) The CEO may authorise a nurse practitioner or a medical practitioner who is not an SPN practitioner to supply or prescribe a stimulant to or for a particular patient on a particular occasion or during a particular period.
(4) An application for an authorisation under subregulation (1) or (3) must be made to the CEO in a form approved by the CEO.
(5) The CEO may grant, or refuse to grant, an authorisation under subregulation (1) or (3) as the CEO thinks fit.
(6) The CEO may grant an authorisation under subregulation (1) or (3) on any terms and conditions the CEO thinks fit.
(7) The CEO may vary or revoke an authorisation under subregulation (1) or (3) at any time by giving written notice to the medical practitioner or nurse practitioner.
(1) A current prescriber or current clinic prescriber for a patient may, by giving an updated notification under regulation 51FE to the CEO —
(a) nominate another medical practitioner or nurse practitioner to be a co‑prescriber for the patient; and
(b) cancel any such nomination.
(2) The nominating prescriber must give a copy of the updated notification given under subregulation (1) to the nominated co‑prescriber.
(3) A nominated co‑prescriber who was nominated by a current prescriber ceases to be a nominated co‑prescriber if —
(a) the current prescriber ceases to be the patient’s current prescriber; or
(b) the current prescriber cancels the nomination under subregulation (1)(b); or
(c) the CEO cancels the co‑prescriber’s nomination under subregulation (7).
(4) A nominated co‑prescriber who was nominated by a current clinic prescriber, ceases to be a nominated co‑prescriber if —
(a) the clinic ceases to be the patient’s current clinic; or
(b) any of the patient’s current clinic prescribers cancels the nomination under subregulation (1)(b); or
(c) the CEO cancels the co‑prescriber’s nomination under subregulation (7).
(5) Subject to subregulation (6), if there is a nominated co‑prescriber for a patient, any other medical practitioner or nurse practitioner who practises in the same medical practice as the nominated co‑prescriber (a
colleague ) is also a co‑prescriber for the patient.(6) Subregulation (5) does not apply in relation to a colleague of the nominated co‑prescriber who is named or described in the nomination as being excluded from being a co‑prescriber under subregulation (5).
(7) The CEO may cancel the nomination of a co‑prescriber by giving written notice to the co‑prescriber.
(8) The CEO must give a copy of a notice given under subregulation (7) to —
(a) if the co‑prescriber was nominated by a current prescriber — that person; or
(b) if the co‑prescriber was nominated by a current clinic prescriber — the manager of the clinic.
(1) The CEO may approve a clinic —
(a) that is, or is part of, a public hospital; and
(b) at which —
(i) treatment is provided for patients who may, in accordance with the Stimulant Prescribing Code, be treated with a stimulant; and
(ii) each patient is not treated exclusively by one SPN practitioner.
(2) An approval must name an SPN practitioner practising at the clinic, or another senior member of the staff of the clinic, as the manager of the clinic.
(3) The manager of an approved clinic must notify the CEO before, or as soon as practicable after, any of the following occurs —
(a) an SPN practitioner commences to practise at the clinic;
(b) an SPN practitioner ceases to practise at the clinic;
(c) there is a change in the name or address of the clinic.
(4) An application for an approval under subregulation (1) must be made to the CEO in a form approved by the CEO.
(5) The CEO may grant, or refuse to grant, an approval under subregulation (1) as the CEO thinks fit.
(6) The CEO may grant an approval under subregulation (1) on any terms and conditions the CEO thinks fit.
(7) The CEO may vary or revoke an approval under subregulation (1) at any time by giving written notice to the manager of the clinic.
(1) If the person named in an approval as the manager of an approved clinic (the
former manager ) —(a) ceases to be an SPN practitioner practising at the clinic or a senior member of the staff of the clinic; or
(b) for any other reason ceases to be the manager of the clinic,
notice of that event must be given to the CEO together with details of the SPN practitioner practising at the clinic or senior member of the staff of the clinic who is to become the manager of the clinic (the
(2) The notice required by subregulation (1) —
(a) may be given by the former manager, the new manager or an SPN practitioner practising at the clinic; and
(b) must be given before, or within 14 days after, the current manager ceases to be manager.
(3) On being notified of a change of manager the CEO must update the clinic’s approval accordingly.
(4) During any period after the former manager ceases to be manager but before the CEO is notified of the new manager, the most senior of the SPN practitioners practising at the clinic is to be taken to be the manager of the clinic.
A medical practitioner shall not supply, issue, write or authorise a prescription for delta‑9‑tetrahydrocannabinol (dronabinol) unless that practitioner has been authorised to do so by the Secretary of the Commonwealth Department of Human Services and Health under section 19 of the
(1) A medical practitioner shall not supply flunitrazepam or issue, write or authorise a prescription for flunitrazepam for a person unless that practitioner has been authorised in writing to do so in relation to that particular person by the CEO.
(2) The CEO shall give the authorisation an identifying number (in this regulation called the
HDWA Authorisation No. ).(3) In an authorisation given under subregulation (1), the CEO may specify that any one or more of the conditions and restrictions set out below apply, namely —
(a) that the prescription be issued by or the treatment be administered by the medical practitioner specified in the authorisation;
(b) that the amount of flunitrazepam to be prescribed or used for treatment shall not exceed the amount specified;
(c) that the amount of flunitrazepam to be prescribed or used on any one day shall not exceed the amount specified;
(d) that the concentration of flunitrazepam to be prescribed shall not exceed the concentration specified;
(e) that the intervals between the issue of prescriptions for flunitrazepam or the administration of flunitrazepam shall be such as are specified;
(f) that the prescription be supplied at the pharmacy specified;
(g) that the amount of flunitrazepam dispensed on a single prescription not exceed such amount as is specified;
(h) that the amount of flunitrazepam that may be supplied on any one day shall not exceed such amount as is specified.
(4) An authorisation issued for the purpose of subregulation (1) is valid for such period as is specified by the CEO unless revoked by the CEO, by notice in writing served on the practitioner, before the expiration of that period.
(5) The CEO may at any time, by notice in writing served on the practitioner, amend the conditions and restrictions specified under subregulation (3).
(6) A medical practitioner shall not supply flunitrazepam or issue, write or authorise a prescription for flunitrazepam contrary to any conditions and restrictions specified in the authorisation.
(7) A medical practitioner who issues or writes a prescription for flunitrazepam shall write the HDWA Authorisation No. on the prescription after his or her signature using the following format —
“HDWA Authorisation No. .................”.
(8) A pharmacist shall not sell or supply flunitrazepam unless the HDWA Authorisation No. is written on the prescription for the flunitrazepam in accordance with subregulation (7).
(1) A dentist shall not write, issue or authorise a prescription or document prescribing the use, sale or supply of a poison included in Schedule 8, or supply a poison included in Schedule 8, unless the poison is also included in the Commonwealth Schedule under the heading “Preparations which may be prescribed by participating dental practitioners for dental treatment only”.
(2) A dentist shall not write, issue or authorise a prescription or document prescribing the use, sale or supply of a poison included in Schedule 8, or supply a poison included in Schedule 8, for the treatment of a person for a period in excess of 7 days, or for periods that in the aggregate over the preceding 12 months exceed 60 days, unless the dentist has first obtained written authorisation to do so from the CEO.
(3) In subregulation (1) —
(1) Subject to the Act and these regulations a drug of addiction shall be dispensed or supplied only in accordance with a prescription complying with the requirements of the regulations.
(2) A medical practitioner, nurse practitioner, endorsed podiatrist, pharmacist, or veterinary surgeon or an assistant under the direct personal supervision of a medical practitioner, nurse practitioner, endorsed podiatrist, pharmacist, or veterinary surgeon shall be the only person who shall dispense a drug of addiction.
(3) The following conditions shall be observed by a person who dispenses a drug of addiction under a prescription —
(a) the dispenser shall satisfy himself or herself —
(i) that the prescription is in accordance with the requirements of the Act; and
(ii) that the person who issued the prescription is a medical practitioner, a nurse practitioner, an endorsed podiatrist, a dentist or a veterinary surgeon; and
(iii) in accordance with subregulation (3a), that the prescription was issued by the prescriber whose name appears on the prescription;
and
(b) the drug of addiction shall not be dispensed under the prescription more than the maximum number of times indicated by the prescription, or at intervals less than those indicated by the prescription; and
(ba) on each occasion on which the drug of addiction is dispensed under the prescription the dispenser shall —
(i) in the case of a prescription that is not issued electronically — sign the prescription clearly in ink using his or her usual signature and clearly indicate the date on which the drug is dispensed; and
(ii) in the case of a prescription that is issued electronically — indicate that the drug of addiction was dispensed and the date on which it was dispensed using the means provided by the approved electronic prescribing system;
and
(bb) on the first occasion on which the drug of addiction is dispensed under the prescription, the dispenser shall —
(i) in the case of a prescription that is not issued electronically — stamp or otherwise mark the prescription clearly in ink with the name and address of the dispensary; and
(ii) in the case of a prescription that is issued electronically — provide, in relation to the prescription, the name and address of the dispensary using the means provided by the approved electronic prescribing system;
and
(c) where the drug of addiction is prescribed by a veterinary surgeon, the dispenser shall not dispense the drug of addiction on more than one occasion under that prescription; and
(d) where the dispenser dispenses less than the prescribed amount of the drug of addiction on a particular occasion and dispenses or intends to dispense the remainder on another occasion or occasions, the dispenser shall on each occasion on which part of the prescribed amount is dispensed —
(i) in the case of a prescription that is not issued electronically — note on the prescription clearly in ink the amount dispensed and the date on which it was dispensed; and
(ii) in the case of a prescription that is issued electronically — indicate, in relation to the prescription, the amount dispensed and the date on which it was dispensed using the means provided by the approved electronic prescribing system;
and
(e) after dispensing the drug of addiction as directed by the prescription the dispenser shall —
(i) indicate, in relation to the prescription, the number of occasions remaining (if any) on which the drug of addiction is to be dispensed under the prescription; and
(ii) in the case of a prescription that is not issued electronically — retain, subject to subregulation (7), the prescription in safe custody at the dispensary;
and
(f) in the case of a prescription that is not issued electronically — the dispenser shall write in ink, or stamp, the word “cancelled” across the prescription in legible letters if —
(i) the prescription does not clearly indicate the maximum number of occasions on which the drug of addiction is to be dispensed under the prescription; or
(ii) the prescription does not clearly indicate the intervals at which the drug of addiction is to be dispensed under the prescription; or
(iii) the drug of addiction has already been dispensed on the maximum number of occasions on which it can lawfully be dispensed under the prescription;
and
(fa) in the case of a prescription that is issued electronically — the dispenser shall indicate that the prescription is cancelled using the means provided by the approved electronic prescribing system if one or more of the conditions in paragraph (f) are met; and
(g) the dispenser shall enter, or cause to be entered, in the register maintained under regulation 44, a proper record of the transaction which record shall be made in such a way as to be easily understood; and
(h) before the drug of addiction is handed to the purchaser, the following particulars shall be recorded in accordance with regulation 52B —
(i) the prescription number;
(ii) the name, address and date of birth of the patient or, in the case of a prescription for veterinary use, the name and address of the person having the care of the animal for which the drug of addiction is prescribed;
(iii) a description of the drug of addiction;
(iv) the quantity of the drug of addiction dispensed;
(v) directions for the use of the drug of addiction;
(vi) the date of the prescription;
(vii) the name and address of the prescriber;
(viii) in the case of a prescription that is not issued electronically — a note of the basis on which the dispenser is satisfied for the purposes of subregulation (3)(a)(iii) that the signature on the prescription is the signature of the prescriber whose name appears on the prescription;
and
[(j) deleted] (k) the label on the bottle or package containing the drug of addiction shall be marked with the prescription number referred to in paragraph (h); and
[(l) deleted] (m) subject to regulation 64, the drug of addiction so dispensed shall conform in quantity, description, composition, strength, form and every other material particular to the directions of the prescriber,
and in respect of a prescription prescribing a poison included in Schedule 8 issued under the
(3a) For the purposes of subregulation (3)(a)(iii), if the prescription is not issued electronically, the dispenser shall orally ask the prescriber whose name appears on the prescription to verify that the prescriber issued the prescription, unless the dispenser is satisfied that the signature on the prescription is the signature of the prescriber on the basis that the dispenser is familiar with the signature of the prescriber and recognises the signature on the prescription as the prescriber’s signature.
(4) A person shall not dispense a drug of addiction under a prescription —
(a) that is more than 6 months old; or
(b) that —
(i) in the case of a prescription that is not issued electronically — is marked “cancelled”; or
(ii) in the case of a prescription that is issued electronically — is cancelled using the means provided by the approved electronic prescribing system.
(5) A person shall not dispense a drug of addiction under a prescription which is illegible or defaced or which appears to have been altered or to be for the purpose of enabling some unauthorised person to obtain a drug of addiction, or which does not appear to be genuine.
(6) If a pharmacist is presented with or accesses a prescription which he or she suspects of being false in any particular he or she shall —
(a) in the case of a prescription that is not issued electronically — retain possession of the prescription for such reasonable period of time as will enable him or her to satisfy the requirements of paragraph (b); and
(b) in any case — make enquiries concerning the genuineness of the prescription, the identity of the person who issued it and the bona fides of the person wishing to have the drug dispensed under it.
(6a) When a pharmacist to whom a prescription is submitted for dispensing a drug of addiction is satisfied that the prescription is not in accordance with the requirements of the Act or regulations, he or she shall —
(a) in the case of a prescription that is not issued electronically —
(i) mark on the prescription “cancelled”, the address of the dispensary and, in his or her own handwriting, the date and his or her usual signature; and
(ii) forward the prescription to the CEO; and
(iii) inform the CEO of the relevant circumstances and the reasons for his or her refusal to dispense the drug of addiction under the prescription;
and
(b) in the case of a prescription that is issued electronically —
(i) cancel the prescription using the means provided by the approved electronic prescribing system; and
(ii) inform the CEO that the prescription has been cancelled, and of the reasons for his or her refusal to dispense the drug of addiction under the prescription.
(7) The dispenser of a drug of addiction may transfer a prescription that is not issued electronically into the safe custody of another person if the transfer is approved by the CEO under subregulation (7a).
(7a) The CEO may, on the oral application of the dispenser, give approval for the dispenser to transfer the prescription to another person by whom the drug can be dispensed in accordance with these regulations.
(8) A pharmacist shall deliver up any document, prescription, authorisation or record relating to the sale or supply of a poison included in Schedule 8 upon request made by an authorised officer.
Any movement of stocks of drugs of addiction other than by prescription and other than supplies received from wholesale suppliers shall be recorded in the manner prescribed by regulation 52B.
(1) The details required to be recorded under regulations 52(3)(h) and 52A shall be —
(a) entered on a duplicate form approved by the CEO; or
(b) entered in a computerised recording system approved by the CEO.
(2) Where the details of a transaction referred to in regulation 52(3)(h) are entered —
(a) on an approved duplicate form, the details shall be entered and signed and dated by the person who actually dispensed the poison;
(b) in an approved computerised recording system, the details shall be accompanied by the name of the person who actually dispensed the poison and the date of the transaction.
(1) Every owner of a pharmacy which dispenses drugs of addiction shall return the original of the completed approved duplicate form or the original of the completed printout of the approved computerised recording system referred to in regulation 52B to the department monthly, by the 7th day of the following month, and where there have been no transactions in the month, the form or printout shall be returned showing the name and address of the pharmacy and marked “NIL”.
(2) Every computer printout returned shall bear the signature of a pharmacist certifying the accuracy and completeness of the data recorded.
(1) If a medical practitioner, nurse practitioner, dentist, endorsed podiatrist or veterinary surgeon in a case of emergency directs, orally or by telephone or other electronic means, the dispensing of a poison included in Schedule 8, he or she shall, within 24 hours, issue to the person by whom the poison was dispensed a prescription complying with regulation 51 that clearly indicates that it is in confirmation of the direction given by him or her under this subregulation.
(2) A person by whom a poison included in Schedule 8 was dispensed in accordance with subregulation (1), shall where the prescription is not received by, or accessible via an approved electronic prescribing system to, him or her within 72 hours, immediately report the circumstances to the CEO.
(1) A person shall not dispense a prescription for or supply upon a prescription any poison included in Schedule 8 unless —
(a) the prescription is issued electronically via an approved electronic prescribing system; or
(b) if the prescription is not issued electronically —
(i) he or she is familiar with the prescriber’s handwriting; or
(ii) he or she has verified with the purported prescriber that the prescription was issued by him or her.
(2) Where a person cannot comply with subregulation (1), for good cause, he or she may dispense the prescription for, or supply upon the prescription, a quantity of the poison included in Schedule 8 sufficient to enable treatment at the rate prescribed for no more than 2 days.
(1) Subject to regulation 53 and to subregulation (3) a poison included in Schedule 8 shall not be delivered to a person except —
(a) on the authority of a written order —
(i) legibly written in ink; and
(ii) bearing on the face thereof —
(I) the date when it is written;
(II) the name and address of the person requiring it to be supplied;
(III) the quantity and description of the poison included in Schedule 8 to be supplied;
and
(iii) signed by a person licensed or otherwise authorised to procure or be in possession of the poison included in Schedule 8;
or
(b) on the authority of an order placed by telephone or telex, but such an order shall be confirmed by the person requiring the poisons to be supplied, by the signing and dating of the dispatch note or invoice delivered with the goods and the dispatch note or invoice shall be returned to the supplier within 7 days of the delivery or the supplier shall notify the CEO of the default.
(2) A poison included in Schedule 8 shall not be delivered to any person not licensed, or otherwise authorised to be in possession of the poison included in Schedule 8, who purports to be sent by or on behalf of the person so licensed or authorised, unless the first‑mentioned person produced an authority in writing signed by the person so licensed or authorised to receive the poison included in Schedule 8 on his or her behalf, and unless the person supplying the poison included in Schedule 8 is satisfied that the authority is genuine.
(3) This regulation does not apply to medicines dispensed in pursuance of the foregoing regulations.
A person forwarding for delivery a drug of addiction shall enclose the poison separately from goods of any other kind in a secure and sturdy package without exterior writing which might indicate the contents of the package and clearly address the package to the authorised person.
A common carrier or his or her employee is hereby authorised to be in possession of any drug of addiction so far only as the possession is necessary for the transport of the drug of addiction in the ordinary course of business.
(1) A person who is —
(a) authorised under regulation 42(1), (2A) or (4); or
(b) licensed under regulation 3,
and who is in possession of a drug or drugs of addiction in an amount that is less than or equal to the amount prescribed by regulation 56A, shall store the poison in a safe of a kind prescribed by clause 1 of Appendix M.
(2) A person who is —
(a) authorised under regulation 42(1) or (2A); or
(b) licensed under regulation 3,
and who is in possession of a drug or drugs of addiction in an amount that is greater than the amount prescribed by regulation 56A, shall store the poison in a safe of a kind prescribed by clause 1 of Appendix M with the additional security requirements prescribed by clause 2 of that Appendix.
(3) Subregulations (1) and (2) do not apply —
(a) to a pharmacist who is in possession of a drug or drugs of addiction in an amount that is less than or equal to the amount prescribed by regulation 56A for the purposes of his or her profession or employment who stores the poison in a safe —
(i) of a type that was prescribed by regulation 56A(2) or (3); and
(ii) that was in place and used by him or her,
immediately before the commencement of the
Poisons Amendment Regulations (No. 2) 1993 1 ; or(aa) to a pharmacist who is in possession of a drug or drugs of addiction in an amount that is greater than the amount prescribed by regulation 56A for the purposes of his or her profession or employment who stores the poison in a safe —
(i) of a type that was prescribed by regulation 56A(2) or (3); and
(ii) that was in place and used by him or her,
immediately before the commencement of the
Poisons Amendment Regulations (No. 2) 1993 1 , if that safe complies with the additional security requirements prescribed by clause 2 of Appendix M; or(b) to a person who has the written permission of the CEO to store a drug of addiction in a manner and with such security arrangements as are specified by the CEO and who stores and secures the drug of addiction in such manner; or
(c) to a person to whom regulation 52(2) applies where that person is in possession of a drug of addiction that he or she has prepared for supply, in accordance with a prescription; or
(d) where a poison included in Schedule 8 in an amount that is no more than would reasonably be required for administration to a patient in an emergency is —
(i) transported by a medical practitioner, nurse practitioner, endorsed midwife, dentist or veterinary surgeon for the purpose of his or her profession or practice; or
(ii) otherwise in the possession of a medical practitioner, nurse practitioner, endorsed midwife, dentist or veterinary surgeon,
if that medical practitioner, nurse practitioner, endorsed midwife, dentist or veterinary surgeon, takes reasonable precautions to protect the poison against theft or loss.
(4) This regulation is subject to regulations 56E and 56G.
(1) For the purposes of regulations 56(1) and (2), the amount is —
(a) 200 tablets or capsules, or tablets and capsules; or
(b) 20 ampoules; or
(c) 500 ml of liquid; or
(d) 7.5 g,
of any poison included in Schedule 8.
(2) A poison included in Schedule 8 in the form of a suppository shall not be included in the assessment of the amount under subregulation (1).
Where a person stores a drug of addiction in a safe in accordance with regulation 56(1) or (2), the person shall ensure that the safe is not in a part of the premises that is accessible to the public unless the person is present in that part of the premises when a member of the public is also present.
Where a person stores a drug of addiction in a safe in accordance with regulation 56(1), (2) or (3)(a), and the safe is of a kind that may be locked by a key, the person shall —
(a) keep the key to the safe in his or her immediate and personal possession; or
(b) ensure that the key to the safe is in the immediate and personal possession of a person who has been authorised by the CEO to have possession of the key.
(1) A person who, under regulation 56C, is in possession of the key to a safe in which is stored a drug of addiction shall ensure that the safe is kept locked at all times except when items are being placed into, or being removed from, the safe.
(2) Where a person stores a drug of addiction in a safe in accordance with regulation 56(1), (2) or (3)(a), and the safe is of a kind that may be locked by a combination lock, the person shall ensure that the safe is kept locked at all times except —
(a) when items are being placed into, or being removed from, the safe; or
(b) during the hours of business if the lock is in the view of the person, in which case and during which time the safe may be unlocked, but shall be closed.
A pharmacist who is —
(a) authorised to be, and is, in possession of a poison included in Schedule 8; and
(b) present on the pharmacy premises,
for the purpose of his or her profession or employment may, instead of storing the poison in accordance with regulation 56(1), (2) or (3)(a), as the case requires, store the drug in a poisons cupboard or in a lockable drawer.
A pharmacist referred to in regulation 56E shall —
(a) keep in his or her immediate and personal possession the key to the poisons cupboard or lockable drawer, as the case may be; and
(b) ensure that the poisons cupboard or lockable drawer, as the case may be, is kept locked at all times except when items are being placed into, or being removed from, the poisons cupboard or lockable drawer.
(1) A poison included in Schedule 8 may be stored in a hospital ward if the poison is stored in —
(a) a lockable cupboard in the ward; or
(b) in a lockable portion of a cupboard in the ward,
where the cupboard, or lockable portion of the cupboard, as the case may be, is used solely for the purpose of storing poisons included in Schedule 8.
(2) A poison included in Schedule 8 may be stored in a hospital ward if the poison is stored in an electronic storage and supply unit that has been installed in accordance with an approval of the CEO under regulation 32G(1).
The registered nurse or registered midwife in charge of a ward in which a poison included in Schedule 8 is stored under regulation 56G(1) shall —
(a) keep in his or her immediate and personal possession the key to the cupboard or lockable portion of the cupboard, as the case may be; and
(b) ensure that the cupboard or lockable portion of the cupboard, as the case may be, is kept locked at all times except when a poison included in Schedule 8 is being placed into, or removed from, the cupboard or lockable portion of the cupboard.
(1) A person shall not supply any drug of addiction unless the package or bottle containing the drug of addiction is plainly labelled or marked to show the quantity of such drug of addiction contained therein.
(2) A person shall not supply any preparation or admixture containing any drug of addiction, unless the package or bottle containing that preparation or admixture is plainly labelled or marked to show the total quantity of such preparation or admixture in the package or bottle and the percentage or quantity of the drug of addiction contained therein, or in the case of tablets or other articles, the number of such tablets or articles in the package or bottle and the percentage or quantity of the drug of addiction contained in each tablet or article.
(3) This regulation does not apply to any drug of addiction, preparation, or admixture dispensed in accordance with these regulations.
(1) A medical practitioner, nurse practitioner, dentist, endorsed podiatrist or veterinary surgeon shall not knowingly give a prescription for a drug of addiction merely for purposes of addiction.
(2) A medical practitioner, nurse practitioner, dentist, authorised health practitioner or veterinary surgeon shall not knowingly supply or administer a drug of addiction merely for purposes of addiction.
A decision of the CEO cancelling, suspending or revoking an authorisation, licence or permit conferred or issued under the Act or these regulations or any other decision of the CEO may be published in the
(1) In this regulation —
(2) If a prescription issued by a medical practitioner, nurse practitioner, dentist or authorised health practitioner prescribes a poison and describes the poison by its approved name, a person dispensing the prescription may dispense or supply any brand of the poison.
(3) Except as provided by this regulation, if a prescription issued by a medical practitioner, nurse practitioner, dentist or authorised health practitioner prescribes a poison and describes the poison by reference to a brand of it, a person dispensing the prescription must not dispense or supply the poison other than in accordance with the description in the prescription.
(4) If a prescription issued by a medical practitioner, nurse practitioner, dentist or authorised health practitioner prescribes a poison and describes the poison by reference to a brand of it, a person dispensing the prescription may dispense or supply any brand of the poison, unless the prescription shows a contrary intention.
(5) If a prescription issued by a medical practitioner, nurse practitioner or an authorised health practitioner in respect of a patient in a public hospital prescribes a poison and describes the poison by reference to a brand of it, a person dispensing the prescription may dispense or supply any brand of the poison, whether or not the prescription indicates a contrary intention.
(6) For the purposes of this regulation, a contrary intention is shown on a prescription if it bears the words “No substitution” or words with a similar effect.
A warrant under section 55A of the Act is to be in the form of Form 15 in Appendix A.
In this Division —
(1) This regulation applies to a person —
(a) who was authorised under regulation 51B(1) (as in force before commencement day) in relation to a drug addict; and
(b) whose authorisation (the
old authorisation ) was in force immediately before commencement day.
(2) The person becomes, on commencement day, a person authorised by the CEO under regulation 51BA(2) for that drug addict on the same terms and conditions as, and (subject to these regulations) for the remainder of the term of, the old authorisation.
(1) This regulation applies to a person —
(a) who was authorised under regulation 51C (as in force before commencement day) in relation to a drug addict; and
(b) whose authorisation (the
old authorisation ) was in force immediately before commencement day.
(2) The person becomes, on commencement day, a person appointed by the CEO under regulation 51CA(1) to be the authorised prescriber for that drug addict on the same terms and conditions as, and (subject to these regulations) for the remainder of the term of, the old authorisation.
Nothing in regulations 51B to 51EA as inserted by the
Regulation 51B (as inserted by the
Name | ||
Address | ||
The poisons included in — o Schedule 1 o Schedule 3 o Schedule 7 o Schedule 2 o Schedule 4 o Schedule 8 to the | ||
Name Qualifications | ||
Name Qualifications | ||
Name Qualifications | ||
Date of issue Date of expiry | |
Form 3
This licence is granted to ....................................................................................... and authorises that person to sell poisons at premises known as .......................... .......................................................................................................................... and
(name of pharmacy)
situated at ...............................................................................................................
.................................................................................................................................
Dated at
Valid until 30 June 20............
.........................................
Form 5
This licence is granted to ............................................................... and authorises that person to procure, and to sell by retail, on behalf of ....................................... the poisons included in Schedule 2 to the
.................................................................................................................................
Dated at
Valid until 30 June 20.............
.........................................
Form 6
This licence is granted to ............................................................... and authorises that person to procure, and sell by retail, on behalf of .........................................., at premises situated at ..........................................................................................., the following poisons included in Schedule 7 —
......................................................................................................................
......................................................................................................................
Subject to the following conditions —
......................................................................................................................
......................................................................................................................
Dated at
Valid until 30 June 20.............
.........................................
Form 6B
This permit is granted to .................................................................................... of ........................................, representative of ............................................, licensed manufacturers of, or wholesale suppliers in, drugs containing poisons included in Schedule 2, 3 or 4 to the
(Name of manufacturers or wholesale suppliers)
and supply them to persons authorised by regulation 8A of the
Dated at
Valid until 30 June 20..............
...........................................
Form 7
This permit is granted to ................................................................................. and authorises that person to purchase on behalf of............................................. —
(a) the poisons included in Schedules ................................................. to the
Poisons Act 1964 ;(b) the following poisons —
.................................................................................................
This permit is issued subject to the following conditions —
(1) the poisons will be stored only at premises situated at ....................
.................................................................................................
(2) the poisons will not be resold;
(3) the poisons will be used only for the following purposes —
.................................................................................................
(4) .................................................................................................
Dated at
Valid until 30 June 20..............
.........................................
Form 8
This permit is granted to ................................................................................. and authorises that person to purchase on behalf of.............................................. —
(a) the poisons included in Schedules ................................................... to the
Poisons Act 1964 ;(b) the following poisons —
.................................................................................................
This permit is issued subject to the following conditions —
(1) the poisons will be stored only at premises situated at .................... ...........................................................................................................
(2) the poisons will not be resold;
(3) the poisons will be used only for the following purposes —
.................................................................................................
.................................................................................................
(4) .................................................................................................
.................................................................................................
Dated at
Valid until 30 June 20..............
.........................................
CEO
Form 8AA
This permit is granted to ................................................................................. and authorises that person to purchase on behalf of ................................ —
(a) the poisons included in Schedules ................................................... to the
Poisons Act 1964 ;(b) the following poisons —
...........................................................................................................
...........................................................................................................
...........................................................................................................
This permit is issued subject to the following conditions —
(1) the poisons will be stored only at premises situated at ...........................................................................................................
(2) the poisons will not be resold;
(3) the poisons will be used only for the following purposes —
...........................................................................................................
...........................................................................................................
...........................................................................................................
(4) ...........................................................................................................
...........................................................................................................
...........................................................................................................
Dated at
Valid until 30 June 20..............
.........................................
CEO
Form 11AA
This permit is granted to ................................................................................. and authorises that person to sell by retail on behalf of ...............................................
................................................................... to any person producing the written order of a veterinary surgeon such mixture containing the following poisons included in Schedule 4 as may be specified in the order, and within the limits as to quantity and composition set out in the order.
Poisons included in Schedule 4 to which this permit applies —
.....................................................................................................................
This permit is issued subject to the following conditions —
(1) the mixture will be stored at and sold from premises situated at
...........................................................................................................
...........................................................................................................
(2) ...........................................................................................................
...........................................................................................................
...........................................................................................................
...........................................................................................................
Dated at
Valid until 30 June 20 ............
.........................................
Form 13
This permit is granted to ................................................................................ and authorises that person to purchase on behalf of ............................................. —
(a) the poisons included in Schedules ................................................... to the
Poisons Act 1964 ;(b) the following poisons —
...........................................................................................................
...........................................................................................................
...........................................................................................................
This permit is issued subject to the following conditions —
(1) the poisons will be stored only at premises situated at ....................
...........................................................................................................
(2) the poisons will not be resold unless the poisons referred to above have been purchased on behalf of a public hospital;
(3) the poisons will be used only for the following purposes —
...........................................................................................................
...........................................................................................................
...........................................................................................................
(4) ...........................................................................................................
...........................................................................................................
...........................................................................................................
...........................................................................................................
Dated at
Valid until 30 June 20............
.........................................
CEO
Form 13A
[Reg. 10B]
(Section 41A)
This licence is granted to ................................................................................. and authorises that person to cultivate*/sell*/purchase*/have in the person’s possession* the following prohibited plants —
.....................................................
.....................................................
.....................................................
.....................................................
.....................................................
.....................................................
at premises situated at ............................................................................................
.................................................................................................................................
subject to the following conditions —
.................................................................................................................................
.................................................................................................................................
.................................................................................................................................
.................................................................................................................................
.................................................................................................................................
Dated: ............................................
Valid until 30 June 20...........
.........................................
CEO
[* delete if not applicable]
Form 14
I ................................................. of ........................................................................ hereby apply on behalf of ...................................................................................... for the approval of the following needle and syringe programme —
.................................................................................................................................
[
.................................................................................................................................
.................................................................................................................................
.................................................................................................................................
1. The programme will be conducted at
......................................................................................................................
[
2. The programme will be conducted at or between the following times —
......................................................................................................................
[
3. The coordinator of the programme will be —
......................................................................................................................
[
.........................................
Signature of Coordinator
Date ............................. ........................................................
Signature of Applicant
Form 15
[Reg. 65]
(Section 55A)
THIS IS A WARRANT authorising an authorised officer under the
Place: Time: (specify hours or at any time) |
This warrant ceases to have effect:
Date: Time: |
I .............................................................................................. Justice of the Peace of ............................................................am satisfied by complaint made on oath that there are reasonable grounds for suspecting that —
(a) an offence against the
Poisons Act 1964 has been, is being or is about to be committed; and(b) there is in or on the premises set out in this warrant, or in a part of those premises (being premises used as a residence) something relevant to the investigation of that offence,
and I authorise ................................................................, an authorised officer, to exercise the entry, search and seizure powers set out in section 55(2) of the
........................................................
Signature of Justice of the Peace
...............................
Date
The authorised officer named in this warrant may, during the time the warrant is effective, exercise the following powers as set out in section 55(2) of the Act —
(a) signal or direct the person in control of a vehicle or vessel —
(i) to stop the vehicle or vessel;
(ii) to move the vehicle or vessel to a place specified by the officer;
(iii) not to move the vehicle or vessel;
(b) enter and search premises, vehicles or vessels using such force as is necessary to gain entry;
(c) break open and search any package, container or other thing in or on premises, vehicles or vessels;
(d) search all persons found in or on premises, vehicles or vessels;
(e) take and remove a sample of anything in or on premises, vehicles or vessels;
(f) seize anything reasonably suspected of being relevant to the investigation of an offence against this Act.
[r. 37B]
1. | Diphtheria toxoid |
2. | Haemophilus B conjugate vaccine |
3. | Haemophilus influenzae vaccine |
4. | Hepatitis A vaccine, inactivated |
5. | Hepatitis B vaccine |
6. | Human papillomavirus vaccine, recombinant |
7. | Influenza virus vaccine |
8. | Measles vaccine, live |
9. | Mumps vaccine, live |
10. | Neisseria meningitidis vaccine |
11. | Pertussis vaccine |
12. | Pneumococcal vaccine |
13. | Poliomyelitis vaccine |
14. | Rotavirus vaccine, live, oral |
15. | Rubella vaccine, live |
16. | Tetanus toxoid |
17. | Varicella zoster vaccine, live attenuated |
[r. 12]
1. | Wholesaler’s licence | 726 | 1 120 | 233 | 564 |
3. | Pharmacist’s licence to sell poisons | 132 | 265 | 99 | 214 |
5. | Licence to sell by retail, poisons included in Schedule 2 | 132 | 199 | 57 | 124 |
6. | Licence to sell by retail, poisons included in Schedule 7 | 228 | 369 | 99 | 214 |
6B. | Poisons permit (distribution of samples) | 132 | 199 | 57 | 124 |
7. | Poisons permit (industrial) — (a) for one or more of the following poisons — benzene; 4,4‑diaminodiphenylmethane (Methylene dianiline); 4,4’‑methylenebis [2-chloroaniline] (MOCA); (b) for poisons other than those set out in paragraph (a) | 575 265 | 1 275 398 | 425 99 | 1 125 223 |
8. | Poisons permit (educational, advisory or research) | 132 | 199 | 57 | 124 |
8AA. | Poisons permit (health services) | 265 | 398 | 99 | 223 |
11AA. | Stockfeed manufacturer’s permit | 174 | 260 | 82 | 165 |
13. | Poisons permit (departmental and hospital) — (a) departmental; (b) hospital | 132 No fee | 199 No fee | 57 No fee | 124 No fee |
Except where otherwise stated, a substance in this Appendix does not include any derivative but does include any compound, preparation or admixture included in relation to that substance in Schedule 4. Where a method of application or of administration is stated in relation to a substance, the entry in this Appendix in relation to that substance applies only to compounds, preparation or admixtures of that substance which have been prepared for that method of application or administration —
Acepromazine Maleate.
Antihistamines.
Apomorphine.
Benzyl penicillin for parenteral injection.
Chlorpromazine (but not to be supplied for use on horses).
Procaine penicillin for parenteral injection.
Streptomycin.
(reg. 35A)
HYDROCORTISONE, when included in Schedule 3.
HYDROCORTISONE ACETATE, when included in Schedule 3.
PSEUDOEPHEDRINE, when included in Schedule 3.
[r. 32B]
The electronic prescribing system must be designed so that —
(a) the system records each person who was given an access code, when it was given and (where relevant) when it was cancelled and each person who has a current access code, in a way that cannot be amended or erased; and
(b) for each entry made in the system —
(i) a unique, sequential number is given to that entry; and
(ii) the time and date is recorded; and
(iii) the system identifier of the person whose access code was used to make the entry is recorded;
and
(c) the system requires that persons with access to it change their access code in accordance with standard industry practice; and
(d) appropriate backup arrangements are in place; and
(e) the system records the details of the administrator or each person who is an administrator of the system, and retains those details for 7 years after the person ceases to be an administrator; and
(f) the system can generate appropriate reports from its records, for example —
(i) of persons with, or who were given, an access code;
(ii) of access to the system, or entries made in the system, during a certain period;
(iii) of entries made in the system during a certain period, sorted according to drug type, strength or dose or according to patient;
(iv) of corrections to entries made during a certain period;
and
(g) the records of the system can be printed.
(Regulations 37 and 51)
1. The computer system shall be designed so that —
(a) the prescription can be generated by the prescriber only;
(b) the prescription is printed on a form which is pre‑printed with the name and address and contact telephone number of the prescriber OR which is pre‑printed with at least the address and contact telephone number of the practice and the system individually prints the name of the prescriber at the foot of the prescription when the prescription is being generated;
(c) either a statement is printed on each prescription form indicating the total number of items prescribed on that form, or the area on the prescription form below the prescriber’s signature is scored, hatched or otherwise marked to prevent any other item being printed in that area;
(d) the directions for use must be determined and included on each occasion by the prescriber;
(e) the particulars of any prescription issued are included in the clinical or prescription record of the person or animal for whom the prescription was generated;
(f) a number which uniquely identifies each prescription form is printed on the form which is related to the clinical or prescription record of the person or animal for whom that prescription was generated;
(g) the clinical or prescription record of the person or animal for whom the prescription was issued is preserved for at least one year from the date on which the prescription was generated and can be accessed when required.
2. For prescriptions of a poison included in Schedule 8 or 9, the words, “The prescriber must write these prescription details in his or her own handwriting” shall be printed by the system immediately below the computer‑printed details, and the system shall allow space on the prescription for these handwritten details.
[Regulations 56(1) and (2)]
A safe for the storage of a drug of addiction shall be either —
(a) a free‑standing safe as follows —
(i) weighing at least 500 kg, but if the weight is less than 1 tonne, then the safe shall be securely bolted through a concrete floor by a person who is licensed under the
Security Agents Act 1976 6 as a security agent or guard to install safes; and(ii) lockable by means of either a key or a combination lock; and
(iii) having a steel plate door at least 12 mm thick, with at least 2 locking bolts that are at least 25 mm thick; and
(iv) having the manufacturer’s recommendation that items with a total value of at least $30 000 stored in the safe be eligible for insurance cover;
or
(b) an under‑floor safe as follows —
(i) embedded in concrete by a person who is licensed under the
Security Agents Act 1976 6 as a security agent or guard to install safes; and(ii) lockable by means of a combination lock; and
(iii) having a heavy cast, high tensile steel lid that is secured at least 25 mm below a steel top plate; and
(iv) having the manufacturer’s recommendation that items with a total value of at least $30 000 stored in the safe be eligible for insurance cover.
(1) A drug or drugs of addiction in an amount greater than the amount prescribed by regulation 56A shall be protected by a detection device complying with the Australian Standard having the designation AS 2201.3 and entitled “Intruder alarm systems Part 3: Detection devices for internal use” published by the Standards Association of Australia
7 including any amendment thereto made before the commencement of thePoisons Amendment Regulations (No. 2) 1993 1 .(2) The detection device shall be able to detect the presence of a person who interferes, or attempts to interfere, with —
(a) the safe in which the poison is, or poisons are, stored; or
(b) the detection device; or
(c) the device’s alarm control panel.
(3) The detection device and its alarm control panel shall be —
(a) monitored by a dedicated direct line; and
(b) installed in compliance with the Australian Standard having the designation AS 2201.1‑1986 and entitled “Intruder alarm systems Part 1: Systems installed in client’s premises”, and by a person who is licensed under the
Security Agents Act 1976 6 as a security agent or guard to install that kind of device and alarm control panel.
29 Jun 1965 p. 1883‑914 | 1 Jul 1965 | |
Untitled regulations | 10 Feb 1966 p. 410 | 10 Feb 1966 |
Untitled regulations | 16 Nov 1966 p. 2935 | 16 Nov 1966 |
Untitled regulations | 14 Jun 1967 p. 1582‑3 | 14 Jun 1967 |
Untitled regulations | 25 Oct 1967 p. 2962 | 25 Oct 1967 |
Untitled regulations | 4 Jun 1968 p. 1694‑5 | 4 Jun 1968 |
Untitled regulations | 28 Nov 1968 p. 3457‑8 | 28 Nov 1968 |
Untitled regulations | 22 Sep 1969 p. 2874‑6 | 22 Sep 1969 |
Untitled regulations | 22 Sep 1969 p. 2877 | 22 Sep 1969 |
Untitled regulations | 9 Feb 1970 p. 370 | 9 Feb 1970 |
Untitled regulations | 12 Aug 1970 p. 2542‑3 | 12 Aug 1970 |
Untitled regulations | 11 Dec 1970 p. 3752 | 11 Dec 1970 |
Untitled regulations | 12 Feb 1971 p. 425 | 12 Feb 1971 |
Untitled regulations | 19 Feb 1971 p. 518‑21 | 19 Feb 1971 |
Untitled regulations | 26 May 1971 p. 1771‑3 | 26 May 1971 |
Untitled regulations | 7 Sep 1971 p. 3277‑9 | 7 Sep 1971 |
Untitled regulations | 23 Dec 1971 p. 5318 | 23 Dec 1971 |
Untitled regulations | 22 Feb 1974 p. 553 | 22 Feb 1974 |
Untitled regulations | 3 May 1974 p. 1434‑5 | 3 May 1974 |
Untitled regulations | 15 Apr 1976 p. 1183 | 15 Apr 1976 |
Untitled regulations | 26 Aug 1977 p. 2966‑73 | 26 Aug 1977 |
Untitled regulations | 4 Nov 1977 p. 4087 | 4 Nov 1977 |
Untitled regulations | 20 Oct 1978 p. 3760 | 20 Oct 1978 |
Untitled regulations | 1 Jun 1979 p. 1437 | 1 Jul 1979 |
Untitled regulations | 5 Oct 1979 p. 3085‑6 | 5 Oct 1979 |
Untitled regulations | 7 Dec 1979 p. 3799‑805 | 7 Dec 1979 |
Untitled regulations | 29 Aug 1980 p. 3027‑31 | 1 Oct 1980 (see |
7 Nov 1980 p. 3746 | 7 Nov 1980 | |
6 Nov 1981 p. 4527 | 6 Nov 1981 | |
16 Jul 1982 p. 2727‑8 | 16 Jul 1982 | |
24 Dec 1982 p. 4904 | 24 Dec 1982 | |
28 Jan 1983 p. 341 | 28 Jan 1983 | |
23 Sep 1983 p. 3803‑7 | 23 Sep 1983 | |
6 Apr 1984 p. 928 (erratum 13 Apr 1984 p. 1020) | 6 Apr 1984 | |
29 Jun 1984 p. 1780‑4 | 1 Jul 1984 (see r. 2) | |
12 Oct 1984 p. 3267 | 12 Oct 1984 | |
8 Feb 1985 p. 519‑20 (erratum 19 Apr 1985 p. 1409) | 8 Feb 1985 | |
8 Feb 1985 p. 520‑1 | 8 Feb 1985 | |
15 Mar 1985 p. 941‑54 (erratum 29 Mar 1985 p. 1110) | 15 Mar 1985 | |
12 Apr 1985 p. 1285‑6 | 1 Jul 1985 (see r. 2) | |
31 May 1985 p. 1882 | 31 May 1985 | |
7 Jun 1985 p. 1941 | 7 Jun 1985 | |
5 Jul 1985 p. 2392 | 5 Jul 1985 | |
20 Sep 1985 p. 3743 | 20 Sep 1985 | |
31 Jan 1986 p. 332‑3 | 31 Jan 1986 | |
28 Feb 1986 p. 616‑17 | 28 Feb 1986 | |
28 Feb 1986 p. 618 | 28 Feb 1986 | |
23 May 1986 p. 1716‑20 (erratum 20 Jun 1986 p. 2049‑54) | 23 May 1986 | |
23 May 1986 p. 1721 (erratum 30 May 1986 p. 1769) | 23 May 1986 | |
11 Jul 1986 p. 2339‑40 | 15 Jul 1986 (see r. 2) | |
1 Aug 1986 p. 2739 | 1 Aug 1986 | |
21 Nov 1986 p. 4269 | 21 Nov 1986 | |
21 Nov 1986 p. 4270 | 21 Nov 1986 | |
5 Dec 1986 p. 4466‑7 | 5 Dec 1986 | |
19 Dec 1986 p. 4874‑5 | 19 Dec 1986 | |
23 Jan 1987 p. 187 | 23 Jan 1987 | |
20 Mar 1987 p. 954 | 20 Mar 1987 | |
15 May 1987 p. 2121 | 15 May 1987 | |
7 Aug 1987 p. 3083‑4 | 7 Aug 1987 | |
18 Sep 1987 p. 3596 | 18 Sep 1987 | |
2 Oct 1987 p. 3776 | 2 Nov 1987 (see r. 2) | |
18 Mar 1988 p. 837 | 18 Mar 1988 | |
18 Mar 1988 p. 838‑52 | 18 Mar 1988 | |
27 May 1988 p. 1769‑71 | 27 May 1988 | |
11 Nov 1988 p. 4443‑4 | 11 Nov 1988 | |
9 Dec 1988 p. 4825 | 9 Dec 1988 | |
2 Jun 1989 p. 1603‑5 | 2 Jun 1989 | |
16 Jun 1989 p. 1742 | 1 Jul 1989 (see r. 3) | |
25 Aug 1989 p. 2842 | 25 Aug 1989 | |
25 Aug 1989 p. 2842 | 25 Aug 1989 | |
6 Oct 1989 p. 3738 | 6 Oct 1989 | |
8 Jun 1990 p. 2626‑7 | 8 Jun 1990 | |
22 Jun 1990 p. 3035 | 22 Jun 1990 | |
17 Aug 1990 p. 4080‑1 | 17 Aug 1990 | |
23 Nov 1990 p. 5790‑2 | 1 Jan 1991 (see r. 2) | |
30 Nov 1990 p. 5908 | 30 Nov 1990 | |
12 Apr 1991 p. 1608‑9 | 12 Apr 1991 | |
14 Jun 1991 p. 2879 | 14 Jun 1991 | |
28 Jun 1991 p. 3149 | 1 Jul 1991 (see r. 2) | |
26 Jul 1991 p. 3854‑5 | 26 Jul 1991 | |
13 Dec 1991 p. 6190‑1 | 13 Dec 1991 | |
16 Apr 1992 p. 1634‑5 | 16 Apr 1992 | |
26 Jun 1992 p. 2700 | 1 Aug 1992 (see r. 2) | |
7 Aug 1992 p. 3864‑6 | 7 Aug 1992 | |
7 Aug 1992 p. 3868‑9 | 7 Aug 1992 | |
28 May 1993 p. 2595‑7 | 28 May 1993 | |
25 Jun 1993 p. 3078‑85 | 25 Jun 1993 | |
9 Jul 1993 p. 3329 | 1 Aug 1993 (see r. 2) | |
1 Oct 1993 p. 5360‑1 | 1 Nov 1993 (see r. 2) | |
12 Nov 1993 p. 6146‑7 | 12 Nov 1993 | |
31 Dec 1993 p. 6883‑5 | 31 Dec 1993 | |
26 May 1994 p. 2195‑201 | 26 May 1994 | |
24 Jun 1994 p. 2854‑5 | 1 Aug 1994 (see r. 2) | |
24 Jun 1994 p. 2864‑70 | 24 Jun 1994 | |
2 Sep 1994 p. 4532‑3 | 2 Sep 1994 | |
16 Sep 1994 p. 4748‑9 | 16 Sep 1994 | |
23 Dec 1994 p. 7076 | 23 Dec 1994 | |
3 Feb 1995 p. 341‑3 | 3 Feb 1995 | |
17 Mar 1995 p. 1026‑7 | 17 Mar 1995 | |
28 Apr 1995 p. 1466 | 28 Apr 1995 | |
28 Apr 1995 p. 1466‑7 | 1 Jun 1995 (see r. 2) | |
27 Jun 1995 p. 2550‑1 | 1 Jul 1995 (see r. 2) | |
5 Sep 1995 p. 4162 | 5 Sep 1995 | |
19 Sep 1995 p. 4382‑4 | 19 Sep 1995 | |
19 Jan 1996 p. 267 | 19 Jan 1996 | |
19 Mar 1996 p. 1216‑39 | 20 Mar 1996 (see r. 2 and | |
23 Aug 1996 p. 4088‑9 | 23 Aug 1996 | |
1 Oct 1996 p. 5088 | 1 Oct 1996 | |
11 Apr 1997 p. 1828‑34 | 11 Apr 1997 | |
17 Mar 1998 p. 1417 | 17 Mar 1998 | |
26 May 1998 p. 2966‑7 | 19 Jun 1998 (see r. 2) | |
27 Nov 1998 p. 6343‑4 | 27 Nov 1998 | |
19 Feb 1999 p. 554‑6 | 19 Feb 1999 | |
29 Feb 2000 p. 992‑5 | 29 Feb 2000 | |
29 Jun 2001 p. 3115‑18 | 29 Jun 2001 | |
14 Aug 2001 p. 4253 | 14 Aug 2001 | |
14 Sep 2001 p. 5073‑7 | 14 Sep 2001 | |
16 Nov 2001 p. 5985 | 16 Nov 2001 | |
13 Aug 2002 p. 4181 | 13 Aug 2002 | |
9 Apr 2003 (see s. 2) | ||
12 Aug 2003 p. 3658‑65 | 12 Aug 2003 | |
5 Oct 2004 p. 4309‑11 | 5 Oct 2004 | |
30 Dec 2004 p. 6943 | 1 Jan 2005 (see r. 2 and | |
4 Jan 2005 p. 3‑4 | 4 Jan 2005 | |
15 Nov 2005 p. 5602‑8 | 1 Jan 2006 (see r. 2) | |
4 Apr 2006 p. 1406‑7 | 4 Apr 2006 | |
15 Dec 2006 p. 5629‑31 | 15 Dec 2006 | |
24 Jul 2007 p. 3663‑5 | r. 1 and 2: 24 Jul 2007 (see r. 2(a)); Regulations other than r. 1 and 2: 25 Jul 2007 (see r. 2(b)) | |
2 Oct 2007 p. 4964‑8 | r. 1 and 2: 2 Oct 2007 (see r. 2(a)); Regulations other than r. 1 and 2: 3 Oct 2007 (see r. 2(b)) | |
7 Nov 2008 p. 4805‑19 | r. 1 and 2: 7 Nov 2008 (see r. 2(a)); Regulations other than r. 1 and 2: 8 Nov 2008 (see r. 2(b)) | |
21 Apr 2009 p. 1359‑67 | r. 1 and 2: 21 Apr 2009 (see r. 2(a)); Regulations other than r. 1 and 2: 22 Apr 2009 (see r. 2(b)) | |
12 Jun 2009 p. 2109‑14 | r. 1 and 2: 12 Jun 2009 (see r. 2(a)); Regulations other than r. 1 and 2: 13 Jun 2009 (see r. 2(b)) | |
28 Jul 2009 p. 2979‑80 | r. 1 and 2: 28 Jul 2009 (see r. 2(a)); Regulations other than r. 1 and 2: 29 Jul 2009 (see r. 2(b)) | |
15 Sep 2009 p. 3571‑2 | r. 1 and 2: 15 Sep 2009 (see r. 2(a)); Regulations other than r. 1 and 2: 16 Sep 2009 (see r. 2(b)) | |
15 Sep 2009 p. 3573‑82 | r. 1 and 2: 15 Sep 2009 (see r. 2(a)); Regulations other than r. 1 and 2: 16 Sep 2009 (see r. 2(b)) | |
25 Sep 2009 p. 3746‑7 | r. 1 and 2: 25 Sep 2009 (see r. 2(a)); Regulations other than r. 1 and 2: 26 Sep 2009 (see r. 2(b)) | |
5 Mar 2010 p. 845‑7 | r. 1 and 2: 5 Mar 2010 (see r. 2(a)); Regulations other than r. 1 and 2: 6 Mar 2010 (see r. 2(b)) | |
26 Mar 2010 p. 1145‑8 | r. 1 and 2: 26 Mar 2010 (see r. 2(a)); Regulations other than r. 1 and 2: 27 Mar 2010 (see r. 2(b)) | |
27 Apr 2010 p. 1583‑4 | r. 1 and 2: 27 Apr 2010 (see r. 2(a)); Regulations other than r. 1 and 2: 28 Apr 2010 (see r. 2(b)) | |
1 Oct 2010 p. 5078‑80 | r. 1 and 2: 1 Oct 2010 (see r. 2(a)); Regulations other than r. 1 and 2: 18 Oct 2010 (see r. 2(b) and | |
22 Oct 2010 p. 5217‑19 | r. 1 and 2: 22 Oct 2010 (see r. 2(a)); Regulations other than r. 1 and 2: 23 Oct 2010 (see r. 2(b)) | |
19 Nov 2010 p. 5709‑10 | r. 1 and 2: 19 Nov 2010 (see r. 2(a)); Regulations other than r. 1 and 2: 20 Nov 2010 (see r. 2(b)) | |
19 Nov 2010 p. 5711‑15 | r. 1 and 2: 19 Nov 2010 (see r. 2(a)); Regulations other than r. 1 and 2: 20 Nov 2010 (see r. 2(b)) | |
1 Apr 2011 p. 1181‑3 | r. 1 and 2: 1 Apr 2011 (see r. 2(a)); Regulations other than r. 1 and 2: 2 Apr 2011 (see r. 2(b)) | |
25 May 2012 p. 2207-8 | r. 1 and 2: 25 May 2012 (see r. 2(a)); Regulations other than r. 1 and 2: 26 May 2012 (see r. 2(b)) | |
1 Jun 2012 p. 2305-26 | r. 1 and 2: 1 Jun 2012 (see r. 2(a)); Regulations other than r. 1 and 2: 2 Jun 2012 (see r. 2(b)) | |
29 Jun 2012 p. 2949-50 | r. 1 and 2: 29 Jun 2012 (see r. 2(a)); Regulations other than r. 1 and 2: 30 Jun 2012 (see r. 2(b)) | |
10 Aug 2012 p. 3803-7 | r. 1 and 2: 10 Aug 2012 (see r. 2(a)); Regulations other than r. 1 and 2: 11 Aug 2012 (see r. 2(b)) | |
29 Nov 2012 (see s. 2) | ||
7 May 2013 p. 1905-6 | r. 1 and 2: 7 May 2013 (see r. 2(a)); Regulations other than r. 1 and 2: 1 Jul 2013 (see r. 2(b)) | |
24 Apr 2014 p. 1146 | r. 1 and 2: 24 Apr 2014 (see r. 2(a)); Regulations other than r. 1 and 2: 25 Apr 2014 (see r. 2(b)) | |
20 May 2014 p. 1598-9 | r. 1 and 2: 20 May 2014 (see r. 2(a)); Regulations other than r. 1 and 2: 1 Jul 2014 (see r. 2(b)) | |
12 Dec 2014 p. 4714‑15 | r. 1 and 2: 12 Dec 2014 (see r. 2(a)); Regulations other than r. 1 and 2: 13 Dec 2014 (see r. 2(b)) | |
16 Dec 2014 p. 4759‑60 | r. 1 and 2: 16 Dec 2014 (see r. 2(a)); Regulations other than r. 1 and 2: 17 Dec 2014 (see r. 2(b)) | |
20 Mar 2015 p. 906‑10 | r. 1 and 2: 20 Mar 2015 (see r. 2(a)); Regulations other than r. 1 and 2: 21 Mar 2015 (see r. 2(b)) | |
17 Apr 2015 p. 1376‑7 | r. 1 and 2: 17 Apr 2015 (see r. 2(a)); Regulations other than r. 1 and 2: 1 Jul 2015 (see r. 2(b)(ii) and | |
5 May 2015 p. 1594‑5 | r. 1 and 2: 5 May 2015 (see r. 2(a)); Regulations other than r. 1 and 2: 1 Jul 2015 (see r. 2(b)) | |
3 Nov 2015 p. 4543-4 | r. 1 and 2: 3 Nov 2015 (see r. 2(a)); Regulations other than r. 1 and 2: 4 Nov 2015 (see r. 2(b)) | |
29 Dec 2015 p. 5174 | r. 1 and 2: 29 Dec 2015 (see r. 2(a)); Regulations other than r. 1 and 2: 30 Dec 2015 (see r. 2(b)) | |
17 May 2016 p. 1489‑90 | 1 Jul 2016 (see r. 2(b)) | |
24 Jun 2016 p. 2311‑15 | 1 Jul 2016 (see r. 2(b) and | |
10 Jan 2017 p. 237‑308 | 24 Jan 2017 (see r. 2(b) and | |
The amendment of an instrument by section 6 or 7 does not prevent that instrument from being amended or repealed by subsequent instrument.
access code..................................................................................... 32A(1), 32F, 44C(1)
Act................................................................................................................................. 2(1)
animal............................................................................................................................ 2(1)
approved clinic......................................................................................................... 51FA
approved computer program................................................................................ 51(1C)
approved electronic prescribing system.................................................................. 2(1)
approved health service..................................................................................... 36AA(1)
approved name.................................................... 35C(4), 36AA(1), 36AAB(1), 64(1)
approved needle and syringe programme............................................................... 2(1)
approved starter pack......................................................................................... 36AA(1)
Australian Register of Therapeutic Goods............................................ 35C(4), 64(1)
authorised health practitioner................................................................................... 2(1)
authorised person....................................................................................... 44(1), 44C(1)
authorised prescriber............................................................................................. 51A(1)
auto-injector............................................................................................................ 41D(1)
book...................................................................................................................... 35A(1A)
brand........................................................................................................................... 64(1)
brand name............................................................................................ 35C(4), 36AA(1)
certificated commercial vessel................................................................................. 2(1)
child............................................................................................................................... 2(1)
child care service................................................................................................... 41D(1)
colleague............................................................................................................... 51FH(5)
commencement day....................................................................................................... 66
Commonwealth Schedule.................................................................................... 51H(3)
Community Emergency Response Team.................................................... 36AAB(1)
coordinator................................................................................................................... 2(1)
co‑prescriber............................................................................................................. 51FA
current clinic............................................................................................................. 51FA
current clinic prescriber.......................................................................................... 51FA
current prescriber..................................................................................................... 51FA
dermatologist............................................................................................................... 2(1)
direction........................................................................................................................ 2(1)
director of nursing....................................................................................................... 2(1)
dispense........................................................................................................................ 2(1)
distribute....................................................................................................................... 2(1)
distributor..................................................................................................................... 2(1)
dosage unit................................................................................................................... 2(1)
drug addict.............................................................................................................. 51A(1)
electronic storage and supply unit............................................................................ 32F
emergency supplies............................................................................................... 36A(4)
endorsed midwife........................................................................................................ 2(1)
endorsed optometrist.................................................................................................. 2(1)
endorsed podiatrist...................................................................................................... 2(1)
entry......................................................................................................................... 44C(1)
experienced person..................................................................................................... 2(1)
exporter................................................................................................................... 39C(5)
external......................................................................................................................... 2(1)
former manager................................................................................................... 51FK(1)
gynaecologist............................................................................................................... 2(1)
HDWA Authorisation No................................................................................. 51GB(2)
height....................................................................................................................... 21A(4)
immediate container................................................................................................... 2(1)
immediate wrapper..................................................................................................... 2(1)
inappropriate use.................................................................................................... 32A(1)
inhaler...................................................................................................................... 41D(1)
livestock.................................................................................................................. 39C(5)
manager...................................................................................................................... 51FA
manufacture................................................................................................................. 2(1)
manufacturer................................................................................................................ 2(1)
master of a ship...................................................................................................... 39C(5)
Medicines List................................................................................................................ 3F
metropolitan region......................................................................................... 36AAB(1)
new manager........................................................................................................ 51FK(1)
new provisions............................................................................................................... 69
NIMC.................................................................................................. 38A(1), 51AAA(1)
nominated co‑prescriber.......................................................................................... 51FA
NRMC..................................................................................................................... 38B(1)
obstetrician................................................................................................................... 2(1)
old authorisation........................................................................................... 67(1), 68(1)
optometrist................................................................................................................... 2(1)
patient......................................................................................................................... 36(1)
permit............................................................................................................................ 2(1)
personal supervision................................................................................................... 2(1)
pharmacist’s licence................................................................................................... 2(1)
pharmacotherapy................................................................................................... 51A(1)
pharmacy...................................................................................................................... 2(1)
physician....................................................................................................................... 2(1)
podiatrist....................................................................................................................... 2(1)
poisons cupboard........................................................................................................ 2(1)
Policies Manual...................................................................................................... 51A(1)
prescribe....................................................................................................................... 2(1)
prescribed medicine....................................................................... 3A(2), 3D(2), 3G(2)
Prescribing Formulary................................................................................................. 3C
prescription..................................................................................................................... 66
proprietary preparation......................................................................................... 8A(16)
psychiatric emergency pack........................................................................... 36AAB(1)
psychiatrist................................................................................................................... 2(1)
public hospital............................................................................................................. 2(1)
qualified person........................................................................................................... 2(1)
quarter........................................................................................................................... 2(1)
racing yacht.................................................................................................................. 2(1)
register..................................................................................................................... 44C(1)
registered midwife...................................................................................................... 2(1)
registered nurse........................................................................................................... 2(1)
remote area nursing post............................................................................................ 2(1)
residential care facility......................................................................................... 38B(1)
Rural Community Mental Health Team...................................................... 36AAB(1)
sale................................................................................................................................. 2(1)
sample...................................................................................................................... 8A(16)
Schedule....................................................................................................................... 2(1)
school....................................................................................................................... 41D(1)
sell................................................................................................................................. 2(1)
specialist prescriber............................................................................................... 51A(1)
specified........................................................................................................................ 3(6)
specified drug......................................................................................................... 8A(1a)
SPN practitioner....................................................................................................... 51FA
starter pack........................................................................................................... 36AA(1)
starter pack instruction...................................................................................... 36AA(1)
stimulant.................................................................................................................... 51FA
Stimulant Prescribing Code.................................................................................... 51FA
supply............................................................................................................................ 2(1)
SUSMP......................................................................................................................... 2(1)
system identifier............................................................................ 32A(1), 32F, 44C(1)
team medical practitioner............................................................................... 36AAB(1)
team psychiatrist.............................................................................................. 36AAB(1)
team registered nurse...................................................................................... 36AAB(1)
to sell............................................................................................................................. 2(1)
0
0
0